<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523417301745</prism:url><dc:identifier>doi:10.1016/j.ejmech.2017.03.017</dc:identifier><eid>1-s2.0-S0223523417301745</eid><prism:doi>10.1016/j.ejmech.2017.03.017</prism:doi><pii>S0223-5234(17)30174-5</pii><dc:title>An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>131</prism:volume><prism:startingPage>196</prism:startingpage><prism:endingPage>206</prism:endingpage><prism:pageRange>196-206</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2017-05-05</prism:coverdate><prism:coverDisplayDate>5 May 2017</prism:coverdisplaydate><prism:copyright>© 2017 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Porta, Federica</dc:creator><dc:creator>Facchetti, Giorgio</dc:creator><dc:creator>Ferri, Nicola</dc:creator><dc:creator>Gelain, Arianna</dc:creator><dc:creator>Meneghetti, Fiorella</dc:creator><dc:creator>Villa, Stefania</dc:creator><dc:creator>Barlocco, Daniela</dc:creator><dc:creator>Masciocchi, Daniela</dc:creator><dc:creator>Asai, Akira</dc:creator><dc:creator>Miyoshi, Nao</dc:creator><dc:creator>Marchianò, Silvia</dc:creator><dc:creator>Kwon, Byoung-Mog</dc:creator><dc:creator>Jin, Yena</dc:creator><dc:creator>Gandin, Valentina</dc:creator><dc:creator>Marzano, Cristina</dc:creator><dc:creator>Rimoldi, Isabella</dc:creator><dc:description>
                  New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization. Ligand 3·HCl showed cytotoxic effects on HCT-116 cells (IC50 = 95.2 μM) and a selective ability to interact with STAT3 (IC50 = 8.2 μM) versus STAT1 (IC50 > 30 μM). Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 μM) and a stronger interaction with STAT3 (IC50 = 1.4 μM), leading to inhibition of its signaling pathway. Pt-3 was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation. In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, Pt-3 showed a higher antitumor activity with fewer side effects than cisplatin.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>DNA-interaction</dcterms:subject><dcterms:subject>Cytotoxic activity</dcterms:subject><dcterms:subject>Platinum diamine complex</dcterms:subject><dcterms:subject>Antitumor agents</dcterms:subject><dcterms:subject>Protein–protein interactions</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523417301745" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523417301745" rel="scidir"/></link></coredata><objects><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="111" size="12736">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="48" size="7083">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="150" size="12954">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="85" size="9188">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="218" height="164" size="12371">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="74" size="12091">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="8311">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="154" size="12126">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="115" size="16071">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="78" size="12661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="11352">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="8466">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="10713">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="183" height="164" size="17179">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="495" height="250" size="37180">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="108" size="20950">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="268" height="183" size="26965">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="206" size="32597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="285" size="33371">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="225" size="44769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="378" height="106" size="25484">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="348" size="46143">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="495" height="260" size="40768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="179" size="45389">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="210" size="29769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="333" height="95" size="23227">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="216" size="40507">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="357" height="320" size="37573">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2193" height="1108" size="167382">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="479" size="76848">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1189" height="812" size="92751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="915" size="155832">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1681" height="1264" size="121674">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2954" height="995" size="215532">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1673" height="471" size="94501">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2189" height="1544" size="226597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2193" height="1150" size="173501">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="792" size="212713">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1681" height="933" size="125832">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1476" height="419" size="75004">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="954" size="250393">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1583" height="1420" size="151101">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="21218419">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417301745-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>85015358887</scopus-id><scopus-eid>2-s2.0-85015358887</scopus-eid><pubmed-id>28324784</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85015358887" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20170315">2017-03-15</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20170315">2017-03-15</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20170318">2017-03-18</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20170318">2017-03-18</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2017-05-31T00:44:40</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523417301745</xocs:eid>
      <xocs:pii-formatted>S0223-5234(17)30174-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523417301745</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2017.03.017</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523417X00056</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20170530">2017-05-30T20:48:35.320534-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20170505</xocs:date-search-begin>
      <xocs:year-nav>2017</xocs:year-nav>
      <xocs:indexeddate epoch="1489591350">2017-03-15T15:22:30.073683Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>131</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>131</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 131</xocs:vol-iss-suppl-text>
      <xocs:sort-order>17</xocs:sort-order>
      <xocs:first-fp>196</xocs:first-fp>
      <xocs:last-lp>206</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>196</xocs:first-page>
         <xocs:last-page>206</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20170505</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 May 2017</xocs:cover-date-text>
      <xocs:cover-date-start>2017-05-05</xocs:cover-date-start>
      <xocs:cover-date-year>2017</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2017 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>INVIVOACTIVE125OXADIAZOLEPTIICOMPLEXAPROMISINGANTICANCERAGENTENDOWEDSTAT3INHIBITORYPROPERTIES</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>PORTA</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>F</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>a. Synthetic strategy</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Characterization</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aqueous stability and lipophilicity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>
                  <ce:italic>In vitro</ce:italic> biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.4.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>AphaScreen-based assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>
                  <ce:italic>In vivo</ce:italic> tumor growth inhibition</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cytotoxic effect of <ce:bold>Pt-3</ce:bold> and <ce:bold>3·HCl</ce:bold> on cell lines poorly sensitive to cisplatin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Intracellular and nuclear accumulation of <ce:bold>Pt-3</ce:bold> and induction of <ce:bold>p53</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>DNA binding study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Glutathione binding study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Effect of <ce:bold>Pt-3</ce:bold> on STAT3 expression and phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>AlexaFluor488-maleimide labeled STAT3 competition assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Physical measurements</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of platinum complexes <ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Crystallization, data collection and structural determination</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.3.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Crystal data</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Stability test</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Log <ce:italic>P</ce:italic>
                     <ce:inf loc="post">ow</ce:inf> determination</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell culture</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>MTT-assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>AlphaScreen-based assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vivo</ce:italic> antitumor activity in Lewis lung carcinoma</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Determination of intracellular and DNA-bound Pt concentrations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Binding study with 9-ethylguanine and GSH</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Luciferase reporter gene assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>AlexaFluor488-maleimide labeled STAT3 competition assay</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.4.9.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Pre-treatment</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.4.9.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Post-treatment</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>ALDERDEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>728</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>ROSENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1969</xocs:ref-pub-year>
            <xocs:ref-first-fp>385</xocs:ref-first-fp>
            <xocs:ref-last-lp>386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ARNESANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2070</xocs:ref-first-fp>
            <xocs:ref-last-lp>2081</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>RAYMOND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>227</xocs:ref-first-fp>
            <xocs:ref-last-lp>235</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>KELLAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>573</xocs:ref-first-fp>
            <xocs:ref-last-lp>584</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>DIPASQUA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>29</xocs:ref-first-fp>
            <xocs:ref-last-lp>35</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>RABIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>9</xocs:ref-first-fp>
            <xocs:ref-last-lp>23</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>FUERTES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>645</xocs:ref-first-fp>
            <xocs:ref-last-lp>662</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>JUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1387</xocs:ref-first-fp>
            <xocs:ref-last-lp>1407</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>GONZALEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>657</xocs:ref-first-fp>
            <xocs:ref-last-lp>663</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>FRASER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>7081</xocs:ref-first-fp>
            <xocs:ref-last-lp>7088</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1159</xocs:ref-first-fp>
            <xocs:ref-last-lp>1168</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>CHE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>255</xocs:ref-first-fp>
            <xocs:ref-last-lp>261</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1139</xocs:ref-first-fp>
            <xocs:ref-last-lp>1142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>PAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e54565</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>81</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>BALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>20669</xocs:ref-first-fp>
            <xocs:ref-last-lp>20679</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1005</xocs:ref-first-fp>
            <xocs:ref-last-lp>1011</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>BOSTROM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1817</xocs:ref-first-fp>
            <xocs:ref-last-lp>1830</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>MASCIOCCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>567</xocs:ref-first-fp>
            <xocs:ref-last-lp>597</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>MATSUNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>ASHIZAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>411</xocs:ref-first-fp>
            <xocs:ref-last-lp>418</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>6911</xocs:ref-first-fp>
            <xocs:ref-last-lp>6920</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>SHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>156</xocs:ref-first-fp>
            <xocs:ref-last-lp>164</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>MENEGHETTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4907</xocs:ref-first-fp>
            <xocs:ref-last-lp>4912</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>MASCIOCCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>592</xocs:ref-first-fp>
            <xocs:ref-last-lp>599</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>FERRI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2538</xocs:ref-first-fp>
            <xocs:ref-last-lp>2547</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>RIMOLDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1907</xocs:ref-first-fp>
            <xocs:ref-last-lp>1913</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>FISHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5613</xocs:ref-first-fp>
            <xocs:ref-last-lp>5615</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>GABRIELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>235</xocs:ref-first-fp>
            <xocs:ref-last-lp>250</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>SAGARREDDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2233</xocs:ref-first-fp>
            <xocs:ref-last-lp>2237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>DREOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>3936</xocs:ref-first-fp>
            <xocs:ref-last-lp>3944</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>EGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2926</xocs:ref-first-fp>
            <xocs:ref-last-lp>2934</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>BERNERSPRICE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>98</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>FARRUGIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>837</xocs:ref-first-fp>
            <xocs:ref-last-lp>838</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>LLORCA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>804</xocs:ref-first-fp>
            <xocs:ref-last-lp>806</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>BONDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1964</xocs:ref-pub-year>
            <xocs:ref-first-fp>441</xocs:ref-first-fp>
            <xocs:ref-last-lp>451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>7639</xocs:ref-first-fp>
            <xocs:ref-last-lp>7651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>PLATTS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>472</xocs:ref-first-fp>
            <xocs:ref-last-lp>474</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>OLDFIELD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>5227</xocs:ref-first-fp>
            <xocs:ref-last-lp>5237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>TETKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1424</xocs:ref-first-fp>
            <xocs:ref-last-lp>1437</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>REIST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>469</xocs:ref-first-fp>
            <xocs:ref-last-lp>473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>MOHR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>352</xocs:ref-first-fp>
            <xocs:ref-last-lp>359</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>KORTYLEWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>315</xocs:ref-first-fp>
            <xocs:ref-last-lp>327</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>MCMURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>216</xocs:ref-first-fp>
            <xocs:ref-last-lp>267</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>ANTIANGIOGENESISDRUGDISCOVERYDEVELOPMENT</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>CHAPTER7STAT3SIGNALINGINCANCERSMALLMOLECULEINTERVENTIONTHERAPY</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>GANDIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1497</xocs:ref-first-fp>
            <xocs:ref-last-lp>1507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>FERRI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2379</xocs:ref-first-fp>
            <xocs:ref-last-lp>2386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>JOHNSTONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2126</xocs:ref-first-fp>
            <xocs:ref-last-lp>2134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>LEMAIRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>271</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>MIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6742</xocs:ref-first-fp>
            <xocs:ref-last-lp>6747</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>JANSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>197</xocs:ref-first-fp>
            <xocs:ref-last-lp>202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54"/></xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>KRAUSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>ALTOMARE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>115</xocs:ref-first-fp>
            <xocs:ref-last-lp>119</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>SHELDRICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>SHELX97PROGRAMSFORCRYSTALSTRUCTUREANALYSISRELEASE972</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>NARDELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>659</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>PLATTS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1199</xocs:ref-first-fp>
            <xocs:ref-last-lp>1207</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>UEHARA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>627</xocs:ref-first-fp>
            <xocs:ref-last-lp>631</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>GRECO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>366</xocs:ref-first-fp>
            <xocs:ref-last-lp>374</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>PORTAX2017X196</xocs:refkey3>
         <xocs:refkey4lp>PORTAX2017X196X206</xocs:refkey4lp>
         <xocs:refkey4ai>PORTAX2017X196XF</xocs:refkey4ai>
         <xocs:refkey5>PORTAX2017X196X206XF</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2019-03-18T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2017 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(17)30174-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523417301745</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523417301745</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2017.03.017</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2017-05-30T20:48:35.320534-04:00</xocs:timestamp>
         <xocs:cover-date-start>2017-05-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/MAIN/application/pdf/883d9ace2cdcd1e4b25f2a1ed350897e/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/MAIN/application/pdf/883d9ace2cdcd1e4b25f2a1ed350897e/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1173401</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523417301745-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/PREVIEW/image/png/33cc796e8a1be2c0bf642f1bb4294857/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/PREVIEW/image/png/33cc796e8a1be2c0bf642f1bb4294857/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>55298</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr7/THUMBNAIL/image/gif/1c719a24c11f6942ea4fbcca4bb162cc/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr7/THUMBNAIL/image/gif/1c719a24c11f6942ea4fbcca4bb162cc/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12736</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc1/THUMBNAIL/image/gif/18b3b3dc9ab928f5f17f3af8d5d0b3ac/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc1/THUMBNAIL/image/gif/18b3b3dc9ab928f5f17f3af8d5d0b3ac/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7083</xocs:filesize>
               <xocs:pixel-height>48</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr3/THUMBNAIL/image/gif/25eed221467650f0f962772c0d5efaf3/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr3/THUMBNAIL/image/gif/25eed221467650f0f962772c0d5efaf3/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12954</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc2/THUMBNAIL/image/gif/ee87458f8ef4f7c4fec40ea8bde11b5e/sc2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc2/THUMBNAIL/image/gif/ee87458f8ef4f7c4fec40ea8bde11b5e/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9188</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr5/THUMBNAIL/image/gif/f8dc88e565c5465ba5077ec23cf3b980/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr5/THUMBNAIL/image/gif/f8dc88e565c5465ba5077ec23cf3b980/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12371</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr10/THUMBNAIL/image/gif/24c823ae18acde1572434ae64a7156be/gr10.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr10/THUMBNAIL/image/gif/24c823ae18acde1572434ae64a7156be/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12091</xocs:filesize>
               <xocs:pixel-height>74</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc3/THUMBNAIL/image/gif/1136c56f1a07de5d5f1440f334b873b0/sc3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc3/THUMBNAIL/image/gif/1136c56f1a07de5d5f1440f334b873b0/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8311</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr2/THUMBNAIL/image/gif/26334c696b6ef3ad45b078446d15e403/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr2/THUMBNAIL/image/gif/26334c696b6ef3ad45b078446d15e403/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12126</xocs:filesize>
               <xocs:pixel-height>154</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr9/THUMBNAIL/image/gif/99ef3bff4f2e19a73ce91845bd8efb2c/gr9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr9/THUMBNAIL/image/gif/99ef3bff4f2e19a73ce91845bd8efb2c/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16071</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/fx1/THUMBNAIL/image/gif/e5ccd2aec72968bb8dc373f0c8fd3593/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/fx1/THUMBNAIL/image/gif/e5ccd2aec72968bb8dc373f0c8fd3593/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12661</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr4/THUMBNAIL/image/gif/f03c6b28a84478d4c8996a1544fe618b/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr4/THUMBNAIL/image/gif/f03c6b28a84478d4c8996a1544fe618b/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11352</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr1/THUMBNAIL/image/gif/1f51fab6a8c2d0d49af0e0168075390c/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr1/THUMBNAIL/image/gif/1f51fab6a8c2d0d49af0e0168075390c/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8466</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr6/THUMBNAIL/image/gif/50ac00ea644675b0e50d40685dcab28d/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr6/THUMBNAIL/image/gif/50ac00ea644675b0e50d40685dcab28d/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10713</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr8/THUMBNAIL/image/gif/19bb5bc19a4f237ef4cbcb61435b4c47/gr8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr8/THUMBNAIL/image/gif/19bb5bc19a4f237ef4cbcb61435b4c47/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17179</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>183</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr7/DOWNSAMPLED/image/jpeg/c4ed45f551f2b46f356ef6b14499ada6/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr7/DOWNSAMPLED/image/jpeg/c4ed45f551f2b46f356ef6b14499ada6/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37180</xocs:filesize>
               <xocs:pixel-height>250</xocs:pixel-height>
               <xocs:pixel-width>495</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc1/DOWNSAMPLED/image/jpeg/2211e6ea6698be5759a8d752c4c3291d/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc1/DOWNSAMPLED/image/jpeg/2211e6ea6698be5759a8d752c4c3291d/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20950</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr3/DOWNSAMPLED/image/jpeg/bbfc5cfeb8159d9c3e857198a4c0ae56/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr3/DOWNSAMPLED/image/jpeg/bbfc5cfeb8159d9c3e857198a4c0ae56/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26965</xocs:filesize>
               <xocs:pixel-height>183</xocs:pixel-height>
               <xocs:pixel-width>268</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc2/DOWNSAMPLED/image/jpeg/f5b92a9287e8c10760495c3c38e85a56/sc2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc2/DOWNSAMPLED/image/jpeg/f5b92a9287e8c10760495c3c38e85a56/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32597</xocs:filesize>
               <xocs:pixel-height>206</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr5/DOWNSAMPLED/image/jpeg/7a5ff1c721bd510c98f4d9a9170d57c0/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr5/DOWNSAMPLED/image/jpeg/7a5ff1c721bd510c98f4d9a9170d57c0/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33371</xocs:filesize>
               <xocs:pixel-height>285</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr10/DOWNSAMPLED/image/jpeg/ea60868a2fddcce866543c1b5400df22/gr10.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr10/DOWNSAMPLED/image/jpeg/ea60868a2fddcce866543c1b5400df22/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44769</xocs:filesize>
               <xocs:pixel-height>225</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc3/DOWNSAMPLED/image/jpeg/f8935bb9bb6e6ce1280b14e105ce3b3b/sc3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc3/DOWNSAMPLED/image/jpeg/f8935bb9bb6e6ce1280b14e105ce3b3b/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25484</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr2/DOWNSAMPLED/image/jpeg/7a6849fde2c261fc2d1bb77b64f38f72/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr2/DOWNSAMPLED/image/jpeg/7a6849fde2c261fc2d1bb77b64f38f72/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46143</xocs:filesize>
               <xocs:pixel-height>348</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr9/DOWNSAMPLED/image/jpeg/09a99086cc37170e8a55eefb8f721c56/gr9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr9/DOWNSAMPLED/image/jpeg/09a99086cc37170e8a55eefb8f721c56/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40768</xocs:filesize>
               <xocs:pixel-height>260</xocs:pixel-height>
               <xocs:pixel-width>495</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/fx1/DOWNSAMPLED/image/jpeg/39995c4e4fb47319842b2555a5b6001c/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/fx1/DOWNSAMPLED/image/jpeg/39995c4e4fb47319842b2555a5b6001c/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45389</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr4/DOWNSAMPLED/image/jpeg/a8779ac11275e9db41ccc42989f0300c/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr4/DOWNSAMPLED/image/jpeg/a8779ac11275e9db41ccc42989f0300c/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29769</xocs:filesize>
               <xocs:pixel-height>210</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr1/DOWNSAMPLED/image/jpeg/62070b9f042bcc15bee8d3a6ff41344e/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr1/DOWNSAMPLED/image/jpeg/62070b9f042bcc15bee8d3a6ff41344e/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23227</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>333</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr6/DOWNSAMPLED/image/jpeg/0b1b5206b8acb6998b556cac3e47d6cb/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr6/DOWNSAMPLED/image/jpeg/0b1b5206b8acb6998b556cac3e47d6cb/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40507</xocs:filesize>
               <xocs:pixel-height>216</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr8/DOWNSAMPLED/image/jpeg/c7718568c9000eda71d695749b661632/gr8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr8/DOWNSAMPLED/image/jpeg/c7718568c9000eda71d695749b661632/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37573</xocs:filesize>
               <xocs:pixel-height>320</xocs:pixel-height>
               <xocs:pixel-width>357</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr7/HIGHRES/image/jpeg/e2ee67efb639be9b57511dce903d41d6/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr7/HIGHRES/image/jpeg/e2ee67efb639be9b57511dce903d41d6/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>167382</xocs:filesize>
               <xocs:pixel-height>1108</xocs:pixel-height>
               <xocs:pixel-width>2193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc1/HIGHRES/image/jpeg/036230a8a0f3b3f81e798206a64d9816/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc1/HIGHRES/image/jpeg/036230a8a0f3b3f81e798206a64d9816/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>76848</xocs:filesize>
               <xocs:pixel-height>479</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr3/HIGHRES/image/jpeg/27918760495294bd9441206cc51ac3ff/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr3/HIGHRES/image/jpeg/27918760495294bd9441206cc51ac3ff/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>92751</xocs:filesize>
               <xocs:pixel-height>812</xocs:pixel-height>
               <xocs:pixel-width>1189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc2/HIGHRES/image/jpeg/ebcbad9ba050c7597952591ad49c4c94/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc2/HIGHRES/image/jpeg/ebcbad9ba050c7597952591ad49c4c94/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>155832</xocs:filesize>
               <xocs:pixel-height>915</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr5/HIGHRES/image/jpeg/ce142619f6f7d8551e61e13d540bf126/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr5/HIGHRES/image/jpeg/ce142619f6f7d8551e61e13d540bf126/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>121674</xocs:filesize>
               <xocs:pixel-height>1264</xocs:pixel-height>
               <xocs:pixel-width>1681</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr10/HIGHRES/image/jpeg/393c1803abf49ee3389463edd628a624/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr10/HIGHRES/image/jpeg/393c1803abf49ee3389463edd628a624/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>215532</xocs:filesize>
               <xocs:pixel-height>995</xocs:pixel-height>
               <xocs:pixel-width>2954</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/sc3/HIGHRES/image/jpeg/d3b588d8101d6474a6e7c1e0576003c9/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/sc3/HIGHRES/image/jpeg/d3b588d8101d6474a6e7c1e0576003c9/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>94501</xocs:filesize>
               <xocs:pixel-height>471</xocs:pixel-height>
               <xocs:pixel-width>1673</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr2/HIGHRES/image/jpeg/a600e8a0d7ef1f76f342d0832043ff21/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr2/HIGHRES/image/jpeg/a600e8a0d7ef1f76f342d0832043ff21/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>226597</xocs:filesize>
               <xocs:pixel-height>1544</xocs:pixel-height>
               <xocs:pixel-width>2189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr9/HIGHRES/image/jpeg/177ea71841ccfe37fbbddcb23416aa81/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr9/HIGHRES/image/jpeg/177ea71841ccfe37fbbddcb23416aa81/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>173501</xocs:filesize>
               <xocs:pixel-height>1150</xocs:pixel-height>
               <xocs:pixel-width>2193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/fx1/HIGHRES/image/jpeg/916ff08c725cee24164b4f0ecaf643b0/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/fx1/HIGHRES/image/jpeg/916ff08c725cee24164b4f0ecaf643b0/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>212713</xocs:filesize>
               <xocs:pixel-height>792</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr4/HIGHRES/image/jpeg/4ac73db2282a7373cbb9505b56579a2e/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr4/HIGHRES/image/jpeg/4ac73db2282a7373cbb9505b56579a2e/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>125832</xocs:filesize>
               <xocs:pixel-height>933</xocs:pixel-height>
               <xocs:pixel-width>1681</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr1/HIGHRES/image/jpeg/d37173a9fe94a7ec8f9ef60ae2757926/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr1/HIGHRES/image/jpeg/d37173a9fe94a7ec8f9ef60ae2757926/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>75004</xocs:filesize>
               <xocs:pixel-height>419</xocs:pixel-height>
               <xocs:pixel-width>1476</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr6/HIGHRES/image/jpeg/c70df70316796e09d61d364af7b77e69/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr6/HIGHRES/image/jpeg/c70df70316796e09d61d364af7b77e69/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>250393</xocs:filesize>
               <xocs:pixel-height>954</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/gr8/HIGHRES/image/jpeg/fa43f89ce036608e195cf5aef035de89/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/gr8/HIGHRES/image/jpeg/fa43f89ce036608e195cf5aef035de89/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>151101</xocs:filesize>
               <xocs:pixel-height>1420</xocs:pixel-height>
               <xocs:pixel-width>1583</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417301745-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417301745/mmc1/MAIN/application/msword/dd99cd7c5fb2d7c74e32a3524bd666c3/mmc1.docx</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417301745/mmc1/MAIN/application/msword/dd99cd7c5fb2d7c74e32a3524bd666c3/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>21218419</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>9277</aid>
            <ce:pii>S0223-5234(17)30174-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2017.03.017</ce:doi>
            <ce:copyright type="full-transfer" year="2017">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">New Pt(II) complexes.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Ligands and their corresponding Pt(II) complexes.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">ORTEP <ce:cross-ref refid="bib37" id="crosref0380">[37]</ce:cross-ref> view of one of the two molecules present in the asymmetric unit of <ce:bold>Pt-1</ce:bold>, showing the arbitrary atom labeling scheme. Ellipsoids are drawn at 40% probability level and H atoms are shown as spheres of arbitrary radius. Selected averaged bond distances (Å): Pt-N1, 1.956(1); Pt-N3, 2.046(1); Pt-Cl1, 2.274(1); Pt-Cl2, 2.294(1); N1-C2, 1.291(1); N3-C3, 1.497(1). Angles (°): N1-Pt-N3, 80.8(1); N3-Pt-Cl1, 90.7(1); Cl1-Pt-Cl2, 91.6(1); Cl2-Pt-N1, 96.8(1); C2-N1-Pt, 119.9(1); C3-N3-Pt, 112.2(1); C2-C3-N3, 110.5(1).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">pH dependent ligand <ce:bold>3</ce:bold> enolization ratio (keto/enol) using RP-HPLC Partisil C-18 ODS.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Body weight changes. The body weight changes of LLC-bearing C57BL mice treated with vehicle or tested compounds. Body weight was measured at day 1 and every two days from day 7 and was taken as a parameter of systemic toxicity. The error bars indicate the SD.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Cytotoxic effects of <ce:bold>Pt-3</ce:bold> complex and cisplatin on DLD-1, HCT-116 and MCF-7 cell lines. Cells were seeded at the density of 40,000/well in a 48 well tray. The day after the medium was replaced with one containing 10% FCS and the reported concentrations of <ce:bold>Pt-3</ce:bold> and cisplatin. After 48 h the cell viability was estimated by MTT assay. Each bar represents the mean ± SD of three determinations. <ce:bold>Pt-3</ce:bold> and cisplatin <ce:italic>vs</ce:italic> control *P < 0.05; **P < 0.01; ***P < 0.001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">DNA and total intracellular concentrations of <ce:sup loc="pre">195</ce:sup>Pt in HCT-116 cell line incubated with <ce:bold>Pt-3</ce:bold> and cisplatin. Cells were seeded (250,000/35 mm petri dish) and incubated with McCoy's supplemented with 10% FCS; 24 h later the medium was replaced with one containing 10% FCS and indicated concentrations of <ce:bold>Pt-3</ce:bold> or cisplatin. After 3 h, the nuclear DNA and total cell homogenates were prepared and <ce:sup loc="pre">195</ce:sup>Pt concentrations determined by ICPMS and normalized with total DNA (A) and protein contents (B).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Effect of <ce:bold>Pt-3</ce:bold> on p53 expression in HCT-116 cell line. Cells were seeded (250,000/35 mm petri dish) and incubated with McCoy's supplemented with 10% FCS; 24 h later the medium was replaced with one containing 10% FCS and the reported concentrations of <ce:bold>Pt-3</ce:bold> and cisplatin. The incubation was continued for a further 24 h at 37 °C and Western blot analysis was performed from total cell lysates. <ce:italic>α</ce:italic>-tubulin antibody was utilized as loading control.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Effect of ligand <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> on STAT3 activity in cultured cells. (<ce:bold>A</ce:bold> and <ce:bold>B</ce:bold>) HCT-116 cells were seeded and incubated with McCoy's supplemented with 10% FCS; 24 h later the medium was replaced with one containing 10% FCS and the reported concentrations of <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold>. The incubation was continued for a further 24 h at 37 °C and Western blot analysis (<ce:bold>A</ce:bold>) were performed from total cell lysates. The ratio of phosphoSTAT3/STAT3 signals are shown in the histogram plot. (<ce:bold>B</ce:bold>) Luciferase reporter assay for STAT3 transcriptional activity was performed in HeLa stable cells pre-incubated for 2 h with reported concentrations of <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold>. The luciferase activity was the stimulated by adding Oncostatin M for 4 h **p < 0.01; ***p < 0.001 <ce:italic>vs</ce:italic> control (Cnt).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">AlexaFluor488-maleimide labeled STAT3 competition assay: a pre-treatment with test compounds assay (<ce:bold>A</ce:bold>) and post-treatment with test compound one (<ce:bold>B</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Reagents and conditions: <ce:italic>i)</ce:italic> NaN<ce:inf loc="post">3</ce:inf>, Ph<ce:inf loc="post">3</ce:inf>P, CCl<ce:inf loc="post">4</ce:inf>/DMF (1:4), 90 °C, 5 h; <ce:italic>ii)</ce:italic> Pd/C, H<ce:inf loc="post">2,</ce:inf> MeOH, 20 atm, 4 h; <ce:italic>iii)</ce:italic> 2 M HCl in Et<ce:inf loc="post">2</ce:inf>O.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/sc1"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Reagents and conditions <ce:italic>i) t</ce:italic>-BuONO, TMSCl, dry THF/DCM, −20 °C to rt, 12 h; <ce:italic>ii)</ce:italic> NH<ce:inf loc="post">2</ce:inf>OH·HCl, NaOH, H<ce:inf loc="post">2</ce:inf>O, reflux, 3 h; <ce:italic>iii)</ce:italic> KOH, Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, ethylen glycol, 160 °C, 1.5 h; <ce:italic>iv)</ce:italic> 2.5 M <ce:italic>n</ce:italic>-BuLi in hexane, methyl benzoate, dry THF, −55 °C for 1 h, then rt for 12 h; <ce:italic>v) t-</ce:italic>BuONO, TMSCl, dry THF, −20 °C to rt, 12 h; <ce:italic>vi)</ce:italic> Zn, TFA, rt, 40 min; <ce:italic>vi)</ce:italic> 2 M HCl in Et<ce:inf loc="post">2</ce:inf>O.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0075">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/sc2"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Reagents and conditions: <ce:italic>i)</ce:italic> K<ce:inf loc="post">2</ce:inf>PtCl<ce:inf loc="post">4</ce:inf>, 4 M HCl, H<ce:inf loc="post">2</ce:inf>O, reflux, 2 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0080">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/sc3"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0010" view="all">Biological properties of the reference (Stattic) and of the oxadiazole derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0085">Table 1</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">MTT assay on HCT116<cross-ref refid="tbl1fna" id="crosref0385">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>(IC<inf loc="post">50</inf>, μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col3" nameend="col4">AlphaScreen<cross-ref refid="tbl1fnb" id="crosref0390">
                              <sup loc="post">b</sup>
                           </cross-ref> (IC<inf loc="post">50</inf>, μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">STAT1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stattic</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">N.E.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">N.E.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">N.T.</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pt-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">122.9 ± 12.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.4 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.2 ± 0.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2·HCl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">N.E.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">N.T.</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pt-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">150 ± 16.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.3 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.9 ± 0.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3·HCl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">95.2 ± 4.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.2 ± 0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pt-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">18.4 ± 6.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.4 ± 0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.9 ± 0.4</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">IC<ce:inf loc="post">50</ce:inf> values measured by MTT assay on HCT-116 cell lines. N.E.: not effective.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0020" view="all">The ability to disrupt the binding of STATs to the cognate pTyr–peptide (5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and FITC-GpYDKPHVL for STAT1) is expressed as IC<ce:inf loc="post">50</ce:inf>. N.T.: not tested.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0015" view="all">
                     <ce:italic>In vivo</ce:italic> antitumor activity toward LLC.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0090">Table 2</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Daily dose <italic>i.p</italic>. (mg·kg<sup loc="post">−1</sup>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Average tumor weight (mean ± SD, g)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibition of tumor growth (%)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead">Control<cross-ref refid="tbl2fna" id="crosref0395">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.582 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead">
                           <bold>Pt-3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.086 ± 0.06**</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">85.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead">
                           <bold>3·HCl</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">75</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.101 ± 0.08**</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">82.6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead">Cisplatin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.073 ± 0.03**</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">87.5</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0020" view="all">**p < 0.01.</ce:simple-para>
               </ce:legend>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Vehicle (20% Cremophor EL (v/v), 20% PEG400 (v/v) and 60% saline solution (v/v));</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">An <ce:italic>in vivo</ce:italic> active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523417301745-8114245fa6fcf8ae0fe0f8aa6f311b3c">
                  <ce:given-name>Federica</ce:given-name>
                  <ce:surname>Porta</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0015">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523417301745-3dd958b3b155e007c6ffe8f24ee5119b">
                  <ce:given-name>Giorgio</ce:given-name>
                  <ce:surname>Facchetti</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0020">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0025">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523417301745-360f9a23f526693cc0f6fabfe4227d1c">
                  <ce:given-name>Nicola</ce:given-name>
                  <ce:surname>Ferri</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0030">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2" id="crosref0035">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au4" author-id="S0223523417301745-e811dae06318cb2185cea34efdf42dba">
                  <ce:given-name>Arianna</ce:given-name>
                  <ce:surname>Gelain</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0040">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor3" id="crosref0045">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" author-id="S0223523417301745-471e62dc18e450c7e4231a53676b7809">
                  <ce:given-name>Fiorella</ce:given-name>
                  <ce:surname>Meneghetti</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0050">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523417301745-67dfc26bf30ca2f75bc65ca8b7807058">
                  <ce:given-name>Stefania</ce:given-name>
                  <ce:surname>Villa</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0055">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523417301745-2bee0402d76fa261253258d3f2c852a7">
                  <ce:given-name>Daniela</ce:given-name>
                  <ce:surname>Barlocco</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0060">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523417301745-04c3eb530308b3c15ca9096a16ebd7a6">
                  <ce:given-name>Daniela</ce:given-name>
                  <ce:surname>Masciocchi</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0065">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523417301745-bbd32b790e599f47c9f14c0fcc41b738">
                  <ce:given-name>Akira</ce:given-name>
                  <ce:surname>Asai</ce:surname>
                  <ce:cross-ref refid="aff3" id="crosref0070">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523417301745-e17a572f9c9ea8d4ed3cad01e65df45a">
                  <ce:given-name>Nao</ce:given-name>
                  <ce:surname>Miyoshi</ce:surname>
                  <ce:cross-ref refid="aff3" id="crosref0075">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11" author-id="S0223523417301745-c99cac896cc989b73dfd0dd6e6895ce4">
                  <ce:given-name>Silvia</ce:given-name>
                  <ce:surname>Marchianò</ce:surname>
                  <ce:cross-ref refid="aff4" id="crosref0080">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au12" author-id="S0223523417301745-2ba472fbad4f3d4d79612f5e229656a0">
                  <ce:given-name>Byoung-Mog</ce:given-name>
                  <ce:surname>Kwon</ce:surname>
                  <ce:cross-ref refid="aff5" id="crosref0085">
                     <ce:sup loc="post">e</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au13" author-id="S0223523417301745-deafe4df483653226a8ed2392f3f574d">
                  <ce:given-name>Yena</ce:given-name>
                  <ce:surname>Jin</ce:surname>
                  <ce:cross-ref refid="aff5" id="crosref0090">
                     <ce:sup loc="post">e</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au14" author-id="S0223523417301745-c4d36663c92119c5f2757c963e5e4ab3">
                  <ce:given-name>Valentina</ce:given-name>
                  <ce:surname>Gandin</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0095">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au15" author-id="S0223523417301745-14c6299e320e133328463e3057e3053e">
                  <ce:given-name>Cristina</ce:given-name>
                  <ce:surname>Marzano</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0100">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au16" orcid="0000-0002-6210-0264" author-id="S0223523417301745-c03629b964bed8f844891daa46896365">
                  <ce:given-name>Isabella</ce:given-name>
                  <ce:surname>Rimoldi</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0105">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0110">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milano, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Dipartimento di Scienze Farmaceutiche</sa:organization>
                     <sa:organization>Università degli Studi di Milano</sa:organization>
                     <sa:address-line>Via L. Mangiagalli 25</sa:address-line>
                     <sa:city>Milano</sa:city>
                     <sa:postal-code>20133</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via Marzolo 5, 35131, Padova, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Dipartimento di Scienze del Farmaco</sa:organization>
                     <sa:organization>Università degli Studi di Padova</sa:organization>
                     <sa:address-line>Via Marzolo 5</sa:address-line>
                     <sa:city>Padova</sa:city>
                     <sa:postal-code>35131</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff3">
                  <ce:label>c</ce:label>
                  <ce:textfn>Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Center for Drug Discovery</sa:organization>
                     <sa:organization>Graduate School of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>University of Shizuoka</sa:organization>
                     <sa:address-line>52-1 Yada</sa:address-line>
                     <sa:address-line>Suruga-ku</sa:address-line>
                     <sa:city>Shizuoka</sa:city>
                     <sa:postal-code>422-8526</sa:postal-code>
                     <sa:country>Japan</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff4">
                  <ce:label>d</ce:label>
                  <ce:textfn>Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Dipartimento di Scienze Farmacologiche e Biomolecolari</sa:organization>
                     <sa:organization>Università degli Studi di Milano</sa:organization>
                     <sa:address-line>Via Balzaretti 9</sa:address-line>
                     <sa:city>Milano</sa:city>
                     <sa:postal-code>20133</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff5">
                  <ce:label>e</ce:label>
                  <ce:textfn>Korea Research Institute of Bioscience and Biotechnology, University of Science and Technology, 125 Gwahakro Yoosunggu, Daejeon 34141, Republic of Korea</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Korea Research Institute of Bioscience and Biotechnology</sa:organization>
                     <sa:organization>University of Science and Technology</sa:organization>
                     <sa:address-line>125 Gwahakro Yoosunggu</sa:address-line>
                     <sa:city>Daejeon</sa:city>
                     <sa:postal-code>34141</sa:postal-code>
                     <sa:country>Republic of Korea</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="8" month="2" year="2017"/></ce:date-received>
            <ce:date-revised day="9" month="3" year="2017"/></ce:date-revised>
            <ce:date-accepted day="10" month="3" year="2017"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">New Pt(II) complexes (<ce:bold>Pt-1-3</ce:bold>) bearing 1,2,5-oxadiazole ligands (<ce:bold>1-3</ce:bold>) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization. Ligand <ce:bold>3·HCl</ce:bold> showed cytotoxic effects on HCT-116 cells (IC<ce:inf loc="post">50</ce:inf> = 95.2 μM) and a selective ability to interact with STAT3 (IC<ce:inf loc="post">50</ce:inf> = 8.2 μM) <ce:italic>versus</ce:italic> STAT1 (IC<ce:inf loc="post">50</ce:inf> > 30 μM). Its corresponding platinum complex <ce:bold>Pt-3</ce:bold> exhibited an increased cytotoxicity (IC<ce:inf loc="post">50</ce:inf> = 18.4 μM) and a stronger interaction with STAT3 (IC<ce:inf loc="post">50</ce:inf> = 1.4 μM), leading to inhibition of its signaling pathway. <ce:bold>Pt-3</ce:bold> was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation. In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, <ce:bold>Pt-3</ce:bold> showed a higher antitumor activity with fewer side effects than cisplatin.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417301745/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>DNA-interaction</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Cytotoxic activity</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Platinum diamine complex</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Antitumor agents</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Protein–protein interactions</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">The development of cisplatin and other cytotoxic metal complexes have contributed to tremendous advances in the field of chemotherapy based on metallorganic entities over the past few decades <ce:cross-refs refid="bib1 bib2 bib3" id="crosrefs0010">[1–3]</ce:cross-refs>. The Food and Drug Administration (FDA)-approved Pt-based anticancer drugs cisplatin, carboplatin and oxaliplatin are still among the most effective drugs used for the treatment of solid cancers <ce:cross-refs refid="bib4 bib5 bib6" id="crosrefs0015">[4–6]</ce:cross-refs>. These Pt-based anticancer agents typically form bifunctional intra- and interstrand DNA cross-links through covalent bonds with purine nucleobases, inhibiting transcription and resulting in cell-death. Unfortunately, the strong side effects and the increasing resistance are limitations to their use, thus evoking the need for new Pt-based chemotherapeutics <ce:cross-refs refid="bib7 bib8 bib9 bib10" id="crosrefs0020">[7–10]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0035" view="all">Literature data highlighted that cisplatin, besides interacting with DNA, was able to modulate mitogen-activated protein kinase (MAPK) family and the phosphoinositide 3 (PI-3)-kinase/Akt pathway <ce:cross-refs refid="bib11 bib12" id="crosrefs0025">[11,12]</ce:cross-refs>. Moreover, many platinum complexes displayed an effective inhibition of signal transducer and activator of transcription 3 (STAT3) cascade <ce:cross-refs refid="bib13 bib14" id="crosrefs0030">[13,14]</ce:cross-refs>, leading to significant clinical benefits. Indeed STAT3 is constitutively activated in a variety of human cancers, including solid tumors, such as breast, prostate and cervical cancers, as well as many leukemias and lymphomas <ce:cross-ref refid="bib15" id="crosref0115">[15]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0040" view="all">In this regard, kinetically liable Pt(IV) complexes inducing tumor regression in mouse colon cancer model, were established to inhibit STAT3 activity in living cells through an irreversible interaction with the STAT3 DNA-binding domains <ce:cross-ref refid="bib13" id="crosref0120">[13]</ce:cross-ref>. The involvement of STAT3 activated cellular responses in cisplatin resistant tumors was highlighted by the ability of Stattic, an effective STAT3 inhibitor, to restore the sensitivity to Pt-based drugs both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> 
                     <ce:cross-refs refid="bib16 bib17" id="crosrefs0035">[16,17]</ce:cross-refs>. Complexes endowed with these dual-targeting features could lead to enhanced therapeutic benefits, as we expect tumor cell apoptosis with minimal side effects <ce:cross-ref refid="bib18" id="crosref0125">[18]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0045" view="all">The effect on STAT3 signaling cascade has been often related to platinum complexes <ce:cross-ref refid="bib13" id="crosref0130">[13]</ce:cross-ref> and small molecules (Stattic and S3I-201) <ce:cross-ref refid="bib19" id="crosref0135">[19]</ce:cross-ref> capability to interact with thiol moiety of cysteines, leading to STAT3 dimerization disruption. Moreover, the disulphide bond-mediated STAT3-dimer formation might be due to the presence of several cysteine residues or vicinal polar residue serving to activate the target cysteine while analogous aggregates through disulphide bond formation haven't been observed related to STAT1 <ce:cross-ref refid="bib20" id="crosref0140">[20]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0050" view="all">Among the molecules disclosed as potential antitumor agents, oxadiazoles have received considerable attention in recent years because of their interesting activity <ce:cross-refs refid="bib21 bib22" id="crosrefs0040">[21,22]</ce:cross-refs>. In this respect, the oxadiazole ring emerged as a key molecular feature for STAT3 inhibition, amongst others, the 1,3,4-oxadiazole characterizes STX-0119 <ce:cross-refs refid="bib23 bib24" id="crosrefs0045">[23,24]</ce:cross-refs>, while the 1,2,5-oxadiazole isomer is present in AVS-0288 <ce:cross-ref refid="bib25" id="crosref0145">[25]</ce:cross-ref>, both known as potent STAT3 inhibitors. All these findings supported our ongoing research focusing on the design of new platinum complexes possibly able to simultaneously interact with DNA and to interrupt STAT3 signaling <ce:cross-ref refid="bib18" id="crosref0150">[18]</ce:cross-ref>. Taking advantage of our experience in the chemistry and biology of the oxadiazole ring <ce:cross-refs refid="bib26 bib27 bib28" id="crosrefs0050">[26–28]</ce:cross-refs> and of platinum compounds <ce:cross-refs refid="bib29 bib30" id="crosrefs0055">[29,30]</ce:cross-refs>, we planned the synthesis of 3-aminomethyl-1,2,5-oxadiazole derivatives as ligands in Pt(II) complexes (<ce:cross-ref refid="fig1" id="crosref0155">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) <ce:cross-ref refid="bib31" id="crosref0160">[31]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:para id="p0055" view="all">In this study, we designed 1,2,5-oxadiazole derivatives and their Pt(II) complexes with the aim to obtain a dual mechanism of action: interfering with DNA replication and inhibiting STAT3 signaling pathway. We devised an aminomethyl moiety as the pivotal feature to be introduced in the 3 position of the oxadiazole ring in order to realize a planar-coordinated Pt(II) drug. Therefore, since our previous research on 1,2,5-oxadiazole derivatives <ce:cross-ref refid="bib27" id="crosref0165">[27]</ce:cross-ref> allowed us to identify <ce:italic>p</ce:italic>-chlorophenyl and benzoyl as useful moieties for STAT3 interaction, starting from the commercially available 3-aminomethyl-4-methyl-1,2,5-oxadiazole (<ce:bold>1</ce:bold>), compound <ce:bold>2</ce:bold> (bearing a <ce:italic>p</ce:italic>-chlorophenyl system at 4-position of the heterocycle) and compound <ce:bold>3</ce:bold> (presenting also a benzoyl group on the aminomethyl chain) were designed and synthesized. Hence, compounds <ce:bold>1</ce:bold>, <ce:bold>2</ce:bold>·<ce:bold>HCl</ce:bold> and <ce:bold>3</ce:bold>·<ce:bold>HCl</ce:bold> were used in coordination with Pt(II) centre. Both ligands and metal complexes (<ce:cross-ref refid="fig2" id="crosref0170">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>) underwent biological evaluation.</ce:para>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">a. Synthetic strategy</ce:section-title>
                     <ce:para id="p0060" view="all">The synthesis of compounds <ce:bold>2, 3, Pt-1, Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold> are shown in <ce:cross-refs refid="sch1 sch2 sch3" id="crosrefs0060">Schemes 1–3</ce:cross-refs>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>.</ce:para>
                     <ce:para id="p0065" view="all">Intermediate <ce:bold>4</ce:bold> was synthesized starting from the commercially available <ce:italic>p</ce:italic>-chlorocinnamic acid, according to the literature <ce:cross-ref refid="bib32" id="crosref0175">[32]</ce:cross-ref>. Azide <ce:bold>5</ce:bold> was prepared by a one pot reaction <ce:cross-ref refid="bib33" id="crosref0180">[33]</ce:cross-ref> in presence of NaN<ce:inf loc="post">3</ce:inf> and Ph<ce:inf loc="post">3</ce:inf>P in CCl<ce:inf loc="post">4</ce:inf>/DMF, and converted to the corresponding amine <ce:bold>2</ce:bold> by catalytic hydrogenation (<ce:cross-ref refid="sch1" id="crosref0185">Scheme 1</ce:cross-ref>). The final product was isolated as hydrochloride salt (<ce:bold>2</ce:bold>·<ce:bold>HCl</ce:bold>).</ce:para>
                     <ce:para id="p0070" view="all">The synthesis of compound <ce:bold>3</ce:bold> (<ce:cross-ref refid="sch2" id="crosref0190">Scheme 2</ce:cross-ref>) started from the commercially available <ce:italic>p</ce:italic>-chloropropiophenone which was treated with <ce:italic>tert</ce:italic>-butyl nitrite and chlorotrimethylsilane to obtain the correspondent <ce:italic>α</ce:italic>-ketooxime <ce:bold>6</ce:bold>. This was converted to the <ce:italic>bis</ce:italic>-oxime <ce:bold>7</ce:bold>, in presence of hydroxylamine hydrochloride and sodium hydroxide <ce:cross-ref refid="bib34" id="crosref0195">[34]</ce:cross-ref>, and then cyclized with potassium hydroxide and cesium carbonate at high temperature to give intermediate <ce:bold>8</ce:bold>. Treatment with <ce:italic>n</ce:italic>-butyl lithium and methyl benzoate gave ketone <ce:bold>9</ce:bold> which underwent an <ce:italic>α</ce:italic>-oximation with <ce:italic>tert</ce:italic>-butyl nitrite and chlorotrimethylsilane. The reduction of compound <ce:bold>10</ce:bold> with zinc in trifluoroacetic acid led to product <ce:bold>3</ce:bold>, purified as hydrochloride salt.</ce:para>
                     <ce:para id="p0075" view="all">A classical methodology was employed for the preparation of the corresponding Pt(II) complexes <ce:cross-ref refid="bib35" id="crosref0200">[35]</ce:cross-ref>. Accordingly, <ce:bold>1</ce:bold>, <ce:bold>2·HCl</ce:bold> and <ce:bold>3·HCl</ce:bold> were treated with K<ce:inf loc="post">2</ce:inf>PtCl<ce:inf loc="post">4</ce:inf> in water in presence of 4 M HCl affording the target compounds <ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold> (<ce:cross-ref refid="sch3" id="crosref0205">Scheme 3</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Characterization</ce:section-title>
                     <ce:para id="p0080" view="all">The identity and purity of all synthesized compounds and their Pt(II) complexes were ascertained by <ce:sup loc="pre">1</ce:sup>H NMR, <ce:sup loc="pre">195</ce:sup>Pt NMR, ESI-MS, elemental analysis and IR (see spectra in SI). The observed chemical shifts (around −2070 ppm) for <ce:sup loc="pre">195</ce:sup>Pt NMR spectra are in the range expected for a Pt(II) core with a N<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> coordination environment, <ce:cross-ref refid="bib36" id="crosref0210">[36]</ce:cross-ref>. In the infrared spectra, the strong absorption around 3200-3100 cm<ce:sup loc="post">−1</ce:sup> corresponding to the <ce:italic>N</ce:italic>-H stretching vibration resulted significantly red shifted in comparison to the corresponding free ligands. The coordination geometry was confirmed by single-crystal X-ray diffraction on the complex <ce:bold>Pt-1</ce:bold>. The ORTEP diagram of <ce:bold>Pt-1</ce:bold> is shown in <ce:cross-ref refid="fig3" id="crosref0215">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor> with selected bond distances and angles. This compound crystallized with two independent molecules in the asymmetric unit, which are almost planar and parallely oriented.</ce:para>
                     <ce:para id="p0085" view="all">The complex <ce:bold>Pt-1</ce:bold> crystallized with two independent molecules in the asymmetric unit with very similar configurations, which are almost planar and parallel oriented. The ORTEP diagram of one molecule is shown in <ce:cross-ref refid="fig3" id="crosref0220">Fig. 3</ce:cross-ref>, with selected bond distances and angles.</ce:para>
                     <ce:para id="p0090" view="all">The determined lengths and angles values are in agreement with the literature for similar Pt(II) complexes <ce:cross-ref refid="bib38" id="crosref0225">[38]</ce:cross-ref>. The Pt(II) atom is coordinated by N atoms of the bidentate ligand and Cl atoms. The coordination environment around the central Pt(II) in both molecules are slightly distorted from an ideal square planar configuration, and the chlorine atoms are <ce:italic>cis</ce:italic> to each other. The angles around Pt atom are close to the expected 90° and 180°. The mean deviation of the PtNNClCl coordination plane is ca. 0.030(6) Å (N1) and the methyl groups lie almost in the same plane of the oxadiazole ring.</ce:para>
                     <ce:para id="p0095" view="all">In the unit cell, two non-equivalent dimers head-to-tail are formed by π–π interactions between individual complexes. These latter are stacked forming molecular layers, parallel to the <ce:italic>ab</ce:italic> plane, where consecutive molecules interact through Pt⋯Pt contacts at 3.612 and 3.3364 Å <ce:cross-ref refid="bib39" id="crosref0230">[39]</ce:cross-ref>, developing chains along the <ce:italic>c</ce:italic> axis <ce:cross-ref refid="bib40" id="crosref0235">[40]</ce:cross-ref> also consolidated by N-H⋯Cl type interactions.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Aqueous stability and lipophilicity</ce:section-title>
                     <ce:para id="p0100" view="all">The aqueous stability for Pt(II) complexes were performed using 0.9% <ce:italic>w/v</ce:italic> NaCl solution in DMF by monitoring UV-vis spectra at their respective <ce:italic>λ</ce:italic>
                        <ce:inf loc="post">max</ce:inf> during a period of 48 h. Each compound was first dissolved in DMF and then diluted with physiological solution to 100 μM final concentration (1% <ce:italic>v/v</ce:italic> DMF). <ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold> demonstrated good stability in physiological solution with negligible variation of their UV peak profile after 48 h (see spectra in SI.</ce:para>
                     <ce:para id="p0105" view="all">The values of log <ce:italic>P</ce:italic>
                        <ce:inf loc="post">ow</ce:inf> were determined using RP-HPLC technique <ce:cross-refs refid="bib41 bib42 bib43" id="crosrefs0065">[41–43]</ce:cross-refs>. The lipophilicity increased along the series (−0.123 and 2.28 for <ce:bold>1</ce:bold> and <ce:bold>2·HCl</ce:bold>, respectively), reaching the maximum value of 1.09 and 3.01 with <ce:bold>3·HCl</ce:bold>. The same trend characterized Pt(II) compounds (−0.773, 2.00 and 2.99 for <ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold> respectively) still satisfying the Lipinski's lipophilicity criterion for druglikeness. Ligand <ce:bold>3</ce:bold> showed a keto-enolic equilibrium responsible for the racemization at the chiral centre <ce:cross-refs refid="bib44 bib45" id="crosrefs0070">[44,45]</ce:cross-refs>, as confirmed by the two values of log <ce:italic>P</ce:italic>
                        <ce:inf loc="post">ow</ce:inf>. Its tautomerism was evaluated at different pH conditions by RP-HPLC (<ce:cross-ref refid="fig4" id="crosref0240">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>): the peaks showed the different ratio between the ketone and the enol species confirming the stability of the compound in all cases.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">
                        <ce:italic>In vitro</ce:italic> biological evaluation</ce:section-title>
                     <ce:para id="p0110" view="all">The ligands and their corresponding complexes were tested by MTT assay for cytotoxic activity and AlphaScreen-based assay to evaluate the effect on STAT3 dimerization.</ce:para>
                     <ce:para id="p0115" view="all">
                        <ce:italic>MTT assay on HCT-116.</ce:italic> The cytotoxic effect of the new ligands and their corresponding Pt(II) complexes was initially assessed in cultured colorectal cancer cells HCT-116. The cell viability was estimated by MTT assay after 48 h incubation with increasing concentrations (10 ÷ 150 μM) of the compounds. As reported in <ce:cross-ref refid="tbl1" id="crosref0245">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>, the ligands generally expressed a negligible (<ce:bold>1</ce:bold> and <ce:bold>2·HCl</ce:bold>) or weak (<ce:bold>3·HCl</ce:bold>) cytotoxic activity (IC<ce:inf loc="post">50</ce:inf> = 95.2 μM). However, the coordination to the platinum centre resulted in an increased cytotoxicity with respect to the free ligand. In particular, <ce:bold>Pt-3</ce:bold> displayed the lowest IC<ce:inf loc="post">50</ce:inf> value (18.4 μM), being about 5 times more effective than the uncoordinated <ce:bold>3·HCl</ce:bold> ligand.</ce:para>
                     <ce:section id="sec2.4.1" view="all">
                        <ce:label>2.4.1</ce:label>
                        <ce:section-title id="sectitle0060">AphaScreen-based assay</ce:section-title>
                        <ce:para id="p0120" view="all">This test is an <ce:italic>in vitro</ce:italic> competitive binding test used to identify compounds able to inhibit the binding of SH2-containing proteins to their correspondent phosphopeptides (5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and FITC-GpYDKPHVL for STAT1). Compounds characterized by an interesting affinity were also investigated for their selectivity <ce:italic>versus</ce:italic> STAT1 having a high degree of sequence homology to STAT3 (78%) but an opposite physiological role <ce:cross-refs refid="bib46 bib47" id="crosrefs0075">[46,47]</ce:cross-refs>. Ligands <ce:bold>1</ce:bold> and <ce:bold>2·HCl</ce:bold> did not disrupt STAT3 dimerization whereas their corresponding Pt(II) complexes <ce:bold>Pt-1</ce:bold> and <ce:bold>Pt-2</ce:bold>, possessed high inhibitory properties. On the other hand, ligand <ce:bold>3·HCl</ce:bold> was shown to selectively interfere with STAT3 (IC<ce:inf loc="post">50</ce:inf> = 8.2 ± 0.1 μM) over STAT1 (IC<ce:inf loc="post">50</ce:inf> value > 30 μM); also its coordination to the Pt(II) centre, similarly to ligands <ce:bold>1</ce:bold> and <ce:bold>2</ce:bold>, improved STAT3 inhibitory activity (IC<ce:inf loc="post">50</ce:inf> = 1.4 ± 0.1 μM) but reduced selectivity <ce:italic>versus</ce:italic> STAT1 (IC<ce:inf loc="post">50</ce:inf> 5.9 ± 0.4 μM). (<ce:cross-ref refid="tbl1" id="crosref0250">Table 1</ce:cross-ref>).</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0065">
                        <ce:italic>In vivo</ce:italic> tumor growth inhibition</ce:section-title>
                     <ce:para id="p0125" view="all">In the light of MTT assay results, the <ce:italic>in vivo</ce:italic> antitumor activity of <ce:bold>Pt-3</ce:bold> and its uncoordinated ligand was evaluated in a model of solid tumor, the syngeneic murine Lewis lung carcinoma (LLC) implanted i.m. in C57BL/6 mice.</ce:para>
                     <ce:para id="p0130" view="all">Tumor growth inhibition induced by <ce:bold>Pt-3</ce:bold> was compared with that promoted by the reference metallo-drug, cisplatin. From day 7 after tumor inoculation, when tumors became visible, tumor-bearing mice received daily i.p. doses of <ce:bold>Pt-3</ce:bold> (30 mg kg<ce:sup loc="post">−1</ce:sup>), <ce:bold>3·HCl</ce:bold> (75 mg kg<ce:sup loc="post">−1</ce:sup>) or cisplatin (1.5 mg kg<ce:sup loc="post">−1</ce:sup>). Cisplatin treatment schedule was selected according to standard protocols designed to optimize its efficacy and minimize the occurrence of adverse events <ce:cross-ref refid="bib48" id="crosref0255">[48]</ce:cross-ref>. For the assessment of the adverse side effects, changes in the body weights of tumor-bearing mice were monitored at day 1 and every two days from day 7 to day 15 (<ce:cross-ref refid="fig5" id="crosref0260">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0135" view="all">The time course of body weight changes, depicted in <ce:cross-ref refid="fig5" id="crosref0265">Fig. 5</ce:cross-ref>, highlights that treatment with <ce:bold>Pt-3</ce:bold> did not induce significant body weight loss, throughout the therapeutic experiment. On the contrary, mice treated with ligand <ce:bold>3·HCl</ce:bold> showed a roughly 15% body weight loss and those treated with cisplatin appeared prostrate and showed substantial (about 27%) weight loss.</ce:para>
                     <ce:para id="p0140" view="all">As shown in <ce:cross-ref refid="tbl2" id="crosref0270">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>, uncoordinated compound <ce:bold>3·HCl</ce:bold> ligand tested at 75 mg kg<ce:sup loc="post">-1</ce:sup> induced a significant tumor growth inhibition that was, however, lower than that promoted by cisplatin. Chemotherapy with <ce:bold>Pt-3</ce:bold> tested at 30 mg kg<ce:sup loc="post">-1</ce:sup> reduced the tumor mass by roughly 85%, only very slightly lower compared with the reference metallo-drug.</ce:para>
                     <ce:para id="p0145" view="all">Overall, these <ce:italic>in vivo</ce:italic> results confirmed that the coordination of STAT3 inhibitor <ce:bold>3·HCl</ce:bold> to a platinum moiety, with the aim to develop a dual action agent, led to the obtainment of an effective antitumor metallo-drug. In addition, <ce:bold>Pt-3</ce:bold> and <ce:bold>3·HCl</ce:bold> appeared to be better tolerated than cisplatin and could be administered at a higher dose.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0070">Cytotoxic effect of <ce:bold>Pt-3</ce:bold> and <ce:bold>3·HCl</ce:bold> on cell lines poorly sensitive to cisplatin</ce:section-title>
                     <ce:para id="p0150" view="all">The cytotoxicity of <ce:bold>Pt-3</ce:bold> was assessed on two additional cancer cell lines less sensitive to cisplatin as compared with HCT-116 cells <ce:cross-ref refid="bib49" id="crosref0275">[49]</ce:cross-ref>, namely the breast cancer cell line MCF-7 and the colorectal cancer cell line DLD-1,. As shown in <ce:cross-ref refid="fig6" id="crosref0280">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>, <ce:bold>Pt-3</ce:bold> did not affect cell viability of MCF-7 at the concentration range of 1÷25 μM, while a significant inhibition of cell viability was observed for DLD-1 cells at 25 μM concentration. As expected, cisplatin showed a limited cytotoxic efficacy on all three cell lines and with no concentration-dependent action (<ce:cross-ref refid="fig6" id="crosref0285">Fig. 6</ce:cross-ref>). MCF-7 cells resulted particularly resistant to both <ce:bold>Pt-3</ce:bold> and cisplatin.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0075">Intracellular and nuclear accumulation of <ce:bold>Pt-3</ce:bold> and induction of <ce:bold>p53</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0155" view="all">To explore the molecular mechanism of action of <ce:bold>Pt-3</ce:bold>, HCT-116 cell line were incubated with the oxadiazole Pt(II) complex (25 and 50 μM) or cisplatin (10 and 25 μM) for 3 h and the <ce:sup loc="pre">195</ce:sup>Pt content was determined from both total cell lysates and nuclear DNA preparations. As shown in <ce:cross-ref refid="fig7" id="crosref0290">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>A, a concentration-dependent accumulation of platinum was observed in the DNA extract after incubation with <ce:bold>Pt-3</ce:bold> and cisplatin. However, the efficiency of <ce:bold>Pt-3</ce:bold> to reach the DNA was significantly lower than cisplatin: at 25 μM the amount of Pt measured was 0.48 ± 0.30 ng Pt/μg DNA and 9.0 ± 0.1 ng Pt/μg DNA for <ce:bold>Pt-3</ce:bold> and cisplatin, respectively. By contrast, the <ce:sup loc="pre">195</ce:sup>Pt concentrations were threefold higher in the total cell lysates of HCT-116 incubated with 25 μM of <ce:bold>Pt-3</ce:bold> as compared to 25 μM of cisplatin (126.6 ng Pt/μg protein and 42.3 ng Pt/μg protein for <ce:bold>Pt-3</ce:bold> and cisplatin, respectively) (<ce:cross-ref refid="fig7" id="crosref0295">Fig. 7</ce:cross-ref>B) <ce:cross-ref refid="bib4" id="crosref0300">[4]</ce:cross-ref>. These data suggest that <ce:bold>Pt-3</ce:bold> has a different subcellular distribution than cisplatin, potentially due to an interaction with a cytoplasmic protein.</ce:para>
                     <ce:para id="p0160" view="all">Although <ce:bold>Pt-3</ce:bold> interacts less efficiently than cisplatin with nuclear DNA, the incubation of HCT-116 cell line with increasing concentrations of platinum complex for 24 h led to a significant induction of p53, as determined by Western blot analysis (<ce:cross-ref refid="fig8" id="crosref0305">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>). These results suggest that <ce:bold>Pt-3</ce:bold> elicited its cytotoxic effect by interacting with nuclear DNA and thus inducing the expression of p53, similarly to cisplatin.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0080">DNA binding study</ce:section-title>
                     <ce:para id="p0165" view="all">To verify the ability of <ce:bold>Pt-3</ce:bold> to interact with deoxyguanosine rich region of DNA, binding studies were performed with the model nucleobase 9-ethylguanine (9-EtG) by using <ce:sup loc="pre">1</ce:sup>H NMR <ce:cross-refs refid="bib50 bib51" id="crosrefs0080">[50,51]</ce:cross-refs>. The <ce:italic>N</ce:italic>
                        <ce:sup loc="post">
                           <ce:italic>7</ce:italic>
                        </ce:sup>of guanine is the putative binding position for the metal centre, thus a downfield chemical shift of the <ce:italic>H</ce:italic>
                        <ce:sup loc="post">
                           <ce:italic>8</ce:italic>
                        </ce:sup> next to <ce:italic>N</ce:italic>
                        <ce:sup loc="post">
                           <ce:italic>7</ce:italic>
                        </ce:sup> in <ce:sup loc="pre">1</ce:sup>H NMR should be observed after binding. The experiment was realized using 0.9% <ce:italic>w/v</ce:italic> NaCl/D<ce:inf loc="post">2</ce:inf>O solution in DMF-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>7</ce:italic>
                        </ce:inf> in order to mimic physiological conditions. In the free 9-EtG, the <ce:italic>H</ce:italic>
                        <ce:sup loc="post">
                           <ce:italic>8</ce:italic>
                        </ce:sup> is characterized by a singlet at 7.68 ppm; however, after 12 h it was possible to evidence the presence of a new singlet at 8.32 ppm, thus confirming the binding between <ce:bold>Pt-3</ce:bold> and 9-EtG. (see spectra in SI.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0085">Glutathione binding study</ce:section-title>
                     <ce:para id="p0170" view="all">Glutathione (GSH), a thiol containing tripeptide, is considered to be responsible of the most drug resistance, especially towards platinum drugs <ce:cross-refs refid="bib8 bib52 bib53" id="crosrefs0085">[8,52,53]</ce:cross-refs>. The GSH binding study with <ce:bold>Pt-3</ce:bold> was conducted using 0.9% <ce:italic>w/v</ce:italic> NaCl/D<ce:inf loc="post">2</ce:inf>O solution in DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>. The <ce:sup loc="pre">1</ce:sup>H NMR spectrum showed the appearance of two multiplets at 3.04–3.09 and 3.10–3.14 ppm that may be assigned to the methylene protons next to SH group which are set at 2.60–2.70 and 2.74–2.82 ppm in the unbound form. These signals underlined the interaction between <ce:bold>Pt-3</ce:bold> and GSH thus limiting the bioavailability of the metal compound. (see spectra in SI.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0090">Effect of <ce:bold>Pt-3</ce:bold> on STAT3 expression and phosphorylation</ce:section-title>
                     <ce:para id="p0175" view="all">The data obtained with the AlphaScreen-based assay clearly demonstrated the capacity of compounds <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> to inhibit the binding between the STAT3-SH2 domain and the phosphotyrosine of the other monomer and, therefore, the STAT3 dimerization. In order to deeply explore the pharmacological activity, we employed a series of experiments aimed at investigating the expression and the phosphorylation state of STAT3. HCT-116 cells were incubated with 25 μM concentration of compounds <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> for 24 h and both total protein extracts were prepared. As shown in <ce:cross-ref refid="fig9" id="crosref0310">Fig. 9</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>A, both compounds did not significantly affect the STAT3 tyrosine phosphorylation state, with a 7.2% and 10.4% inhibition after incubation with <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold>, respectively.</ce:para>
                     <ce:para id="p0180" view="all">The direct measurements of the STAT3 promoter activity by luciferase assay in HeLa cells, showed that <ce:bold>Pt-3</ce:bold> significantly interfered with STAT3 function with an IC<ce:inf loc="post">50</ce:inf> value equal to 16.7 μM, close to the value observed in the MTT cytotoxicity assay (<ce:cross-ref refid="fig9" id="crosref0315">Fig. 9</ce:cross-ref>C and <ce:cross-ref refid="tbl1" id="crosref0320">Table 1</ce:cross-ref>). On the contrary, compound <ce:bold>3·HCl</ce:bold>, did not show any significant activity at the maximal concentration tested (30 μM), confirming its lower cytotoxic effect.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.11" view="all">
                     <ce:label>2.11</ce:label>
                     <ce:section-title id="sectitle0095">AlexaFluor488-maleimide labeled STAT3 competition assay</ce:section-title>
                     <ce:para id="p0185" view="all">To suggest a possible mechanism by which dimerization disruption occurred in the presence of compound <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold>, competitive experiments were performed using AlexaFluor488-maleimide labeled STAT3, able to discriminate the interaction site on STAT3 for both the compounds. The results obtained in two different types of experiments are reported in <ce:cross-ref refid="fig10" id="crosref0325">Fig. 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>: a pre-treatment with test compounds assay (<ce:bold>A</ce:bold>) and post-treatment with test compound one (<ce:bold>B</ce:bold>). AlexaFluor488-maleimide reduced <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> ability to interact with cysteine residues resulting in lower inhibitory effect. We can speculate that the partial residual activity shown by <ce:bold>Pt-3</ce:bold> might be due to the coordination of platinum metal centre to the thiol groups as expected also in the case of <ce:bold>Pt-1</ce:bold> and <ce:bold>Pt-2</ce:bold>. On the contrary, the lower affinity of compound <ce:bold>3·HCl</ce:bold> for cysteines than AlexaFluor488-maleimide led to a total loss of effect. The AlphaScreen-based assay results confirmed <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> capability to disrupt STAT3 dimerization without influencing the phosphorylation as reported before by our experimental data (see <ce:cross-ref refid="fig9" id="crosref0330">Fig. 9</ce:cross-ref>A).</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0100">Conclusions</ce:section-title>
                  <ce:para id="p0190" view="all">Our study aimed to disclose a Pt(II) complex able to interfere with DNA replication and to inhibit STAT3 signaling cascade. In order to achieve this goal, we selected a 3-aminomethyl-1,2,5-oxadiaxole scaffold as ligand for the preparation of Pt(II) complexes. This based-structure was differently substituted to allow the modulation of cytotoxicity and affinity/selectivity for STAT3.</ce:para>
                  <ce:para id="p0195" view="all">Regarding the <ce:italic>in vitro</ce:italic> experiments, <ce:bold>Pt-1</ce:bold> and <ce:bold>Pt-2</ce:bold> showed a higher inhibitory effect in AlphaScreen-based assay in comparison with <ce:bold>Pt-3</ce:bold> but a negligible cytotoxicity. The 9-EtG results, the induction of p53 determined by Western blot analysis and the presence of <ce:sup loc="pre">195</ce:sup>Pt in DNA extracted from treated HCT-116 cells suggested an interaction with nuclear DNA, although the molecular mechanism of cytotoxicity still needs to be determined. In addition, <ce:bold>Pt-3</ce:bold> did not significantly inhibit the phosphorylation state of STAT3 in HCT-116 cells, but significantly affected the STAT3 promoter activity and thiol modification. All these results supported a possible dual targeting mechanism of <ce:bold>Pt-3</ce:bold>. Digestive LC-MS/MS fragmentation spectroscopy and other biochemical approaches will be employed to fully understand the interaction of <ce:bold>3·HCl</ce:bold> and <ce:bold>Pt-3</ce:bold> with specific cysteines of STAT3 domain.</ce:para>
                  <ce:para id="p0200" view="all">
                     <ce:italic>In vivo</ce:italic> studies carried out in the highly aggressive Lewis Lung Carcinoma (LLC) model confirmed that the coordination of STAT3 inhibitor <ce:bold>3·HCl</ce:bold> to a platinum moiety led to the obtainment of an effective antitumor metallo-drug.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0105">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0110">Materials and methods</ce:section-title>
                     <ce:para id="p0205" view="all">Reagents and solvents were purchased from Sigma-Aldrich and used without further purification. Some reactions involving air-sensitive reagents were performed under nitrogen atmosphere and anhydrous solvents were used when necessary. Reactions were monitored by thin layer chromatography analysis on aluminum-backed Silica Gel 60 plates (70–230 mesh, Merck), using an ultraviolet fluorescent lamp at 254 nm and 365 nm. Visualization was aided by opportune staining reagents. Purification of intermediates and the final compounds was performed by flash chromatography using Geduran<ce:sup loc="post">®</ce:sup> Si 60 (40–63 μm, Merck). HCT-116 cell line (colorectal cancer) were cultured in McCoy's media, the DLD-1 (colorectal cancer) and MCF-7 were cultured in Dulbecco's modified eagle's medium (DMEM) with glutamine. All the media were supplemented with penicillin (10,000 U/mL), streptomycin (10 mg/mL), nonessential amino acid and 10% Fetal Calf Serum (FCS). The same media was utilized for the experiments where cells were incubated with newly synthesized compounds dissolved in DMSO. The same volume of solvent was added to control conditions and did not exceed 0.5% v/v.: HCT 116 ATCC<ce:sup loc="post">®</ce:sup> number CCL 247™; MCF7: ATCC<ce:sup loc="post">®</ce:sup> number HTB-22™, DLD1: ATCC<ce:sup loc="post">®</ce:sup> number CCL-221™, HELA: ATCC<ce:sup loc="post">®</ce:sup> number CCL-2™ and STAT3-HeLa SL-0003 (from Signosis).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0115">Physical measurements</ce:section-title>
                     <ce:para id="p0210" view="all">
                        <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C NMR spectra were recorded in CDCl<ce:inf loc="post">3</ce:inf>, CD<ce:inf loc="post">3</ce:inf>OD, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> or DMF-d<ce:inf loc="post">7</ce:inf> on Bruker DRX Avance 300 MHz or on a Variant 300 MHz Oxford equipped with a non-reverse probe at 25 °C. Chemical shifts (in ppm) were referenced to residual solvent proton/carbon peak. Chemical shifts are expressed as <ce:italic>δ</ce:italic> (ppm). Multiplicity is reported as <ce:italic>s</ce:italic> (singlet), <ce:italic>br s</ce:italic> (broad singlet), <ce:italic>d</ce:italic> (double), <ce:italic>t</ce:italic> (triplet), <ce:italic>q</ce:italic> (quartet), <ce:italic>m</ce:italic> (multiplet), <ce:italic>dd</ce:italic> (double of doublets), <ce:italic>dt</ce:italic> (doublet of triplets). The coupling constants (J-values) are given in Hertz (Hz). All spectroscopic data match the assigned structures. FTIR spectra were collected by using a Perkin Elmer (MA, USA) FTIR Spectrometer “Spectrum One” in a spectral region between 4000 and 450 cm<ce:sup loc="post">−1</ce:sup> and analyzed by transmittance technique with 32 scansions and 4 cm<ce:sup loc="post">−1</ce:sup> resolution. ESI-MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ Advantage system MS spectrometer with an electronspray ionisation source and an ‘Ion Trap’ mass analyzer. The MS spectra were obtained by direct infusion of a sample solution in MeOH under ionisation, ESI positive. Log <ce:italic>P</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>ow</ce:italic>
                        </ce:inf>'s values and purity were evaluated with Partisil C18-ODS reversed-phase HPLC column with Merck-Hitachi L-7100 equipped with Detector UV6000LP. Elemental analyses were performed using a Perkin Elmer SeriesII/CHNS/O 2400 Analyzer. ICP-MS data were recorded with BRUKER aurora M90 ICP-MS (MA, USA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0120">Chemistry</ce:section-title>
                     <ce:section id="sec4.3.1" view="all">
                        <ce:label>4.3.1</ce:label>
                        <ce:section-title id="sectitle0125">General procedure for the synthesis of platinum complexes <ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0215" view="all">An amount of K<ce:inf loc="post">2</ce:inf>PtCl<ce:inf loc="post">4</ce:inf> (1 mmol) was dissolved in 10 mL of distilled water. Ligand (1.1 mmol) when available in dihydrochloride form was preventively neutralized with NaHCO<ce:inf loc="post">3</ce:inf> aqueous solution and was dropped into palatinate solution. 4 M HCl (10 equivalents) was added and the mixture was refluxed under nitrogen atmosphere for 12 h. After cooling to room temperature, the product was filtered as a solid and washed extensively with water. The precipitate was then dissolved in diethyl ether and crystallized for slow diffusion of hexane.</ce:para>
                        <ce:para id="p0220" view="all">
                           <ce:bold>Pt-1</ce:bold>: pale-yellow solid, 62% yield. Chemical Formula: C<ce:inf loc="post">4</ce:inf>H<ce:inf loc="post">7</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>OPt. Molecular Weight: 377.96 g/mol. <ce:sup loc="pre">1</ce:sup>H NMR (300 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> 6.72 (br, 2H), 4.34 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 2.61 (s, 3H) ppm. <ce:sup loc="pre">13</ce:sup>C NMR (75 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) 163.18, 153.94, 42.79, 8.64 ppm. <ce:sup loc="pre">195</ce:sup>Pt NMR (300 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> −2065 ppm. Elemental analysis for C<ce:inf loc="post">4</ce:inf>H<ce:inf loc="post">7</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>OPt: calculated C, 12.67; H, 1.81; N, 11.09; found C, 12.72; H, 1.78; N, 10.98, IR <ce:italic>ν</ce:italic> = 3217, 3188, 3103, 1586, 1567, 1426, 1376, 1201, 1050, 970 cm<ce:sup loc="post">−1</ce:sup>, MS (ESI) <ce:italic>m/z</ce:italic> 365.9 [M-Cl + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0225" view="all">
                           <ce:bold>Pt-2</ce:bold>: brown solid, 45% yield. Chemical Formula: C<ce:inf loc="post">9</ce:inf>H<ce:inf loc="post">8</ce:inf>Cl<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>OPt. Molecular Weight: 473.94 g/mol. <ce:sup loc="pre">1</ce:sup>H NMR (300 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> 7.98 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 7.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.94 (br, 2H), 4.61 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 2H) ppm. <ce:sup loc="pre">13</ce:sup>C NMR (75 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) 137.78, 130.49, 130.19, 125.25, 123.31, 116.47, 44.35 ppm. <ce:sup loc="pre">195</ce:sup>Pt NMR (300 MHz, DMF-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>7</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> −2075 ppm. Elemental analysis for C<ce:inf loc="post">9</ce:inf>H<ce:inf loc="post">8</ce:inf>Cl<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>OPt: calculated C, 22.93; H, 1.70; N, 8.84; found C, 23.01; H, 1.75; N, 8.89, IR <ce:italic>ν</ce:italic> = 3243, 3204, 2962, 2919, 1602, 1567, 1464, 1261, 1096, 1016, 802 cm<ce:sup loc="post">−1</ce:sup>, MS (ESI) <ce:italic>m/z</ce:italic> 461.9 [M-Cl + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0230" view="all">
                           <ce:bold>Pt-3</ce:bold>: olive-green solid, 61% yield. Chemical Formula: C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">12</ce:inf>Cl<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf>Pt. Molecular Weight: 577.96 g/mol. <ce:sup loc="pre">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.77 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.50–7.44 (m, 5H), 7.25–7.21 (m, 2H), 6.20 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 5.46–5.41 (m, 1H), 4.88–4.85 (m, 1H) ppm. <ce:sup loc="pre">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) 191.27, 152.84, 149.45, 138.06, 135.09, 132.73, 130.44, 130.35, 130.23, 130.19, 129.60, 129.51, 129.47, 129.32, 129.23, 128.93, 55.15 ppm. <ce:sup loc="pre">195</ce:sup>Pt NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> −2068 ppm. Elemental analysis for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">12</ce:inf>Cl<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf>Pt: calculated C, 33.35; H, 2.13; N, 7.45; found C, 33.58; H, 2.18; N, 7.54, IR <ce:italic>ν</ce:italic> = 3145, 3078, 2931, 1697, 1597, 1448, 1261, 1216, 1094, 995, 960, 834, 688 cm<ce:sup loc="post">−1</ce:sup>, MS (ESI) <ce:italic>m/z</ce:italic> 578.5 [M+H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.2" view="all">
                        <ce:label>4.3.2</ce:label>
                        <ce:section-title id="sectitle0130">Crystallization, data collection and structural determination</ce:section-title>
                        <ce:para id="p0235" view="all">Single crystals of <ce:bold>Pt-1</ce:bold> suitable for X-ray structure analysis were obtained by slow evaporation of a solution 33% MeOH:water at room temperature. The crystals were small yellow needles. Intensity data were collected at room temperature on a Bruker Axs CCD-based three cycle diffractometer, using graphite-monochromatized Mo-K radiation (λ = 0.71073 Å).</ce:para>
                        <ce:para id="p0240" view="all">X-ray diffraction data in the θ range 2–25° were collected acquiring 4 sets of 600 bidimensional CCD frames with the following operative conditions: omega rotation axis, scan width 0.3°, acquisition time 40 s, sample-to-detector distance 50 mm, phi angle fixed at four different values (0°, 90°, 180°, 270°) for the four different sets.</ce:para>
                        <ce:para id="p0245" view="all">Omega-rotation frames were processed with the SAINT software <ce:cross-ref refid="bib54" id="crosref0335">[54]</ce:cross-ref> for data reduction (including intensity integration, background, Lorentz and polarization corrections) and for determination of accurate unit-cell dimensions, obtained by least-squares refinement of the positions of 8049 independent reflections with I > 10σ(I) in the θ range 2–24°. Absorption effects were empirically evaluated by the SADABS software <ce:cross-ref refid="bib55" id="crosref0340">[55]</ce:cross-ref> and absorption correction was applied to the data (0.367 and 0.602 min and max transmission factor).</ce:para>
                        <ce:para id="p0250" view="all">The structure was solved by direct methods (<ce:italic>SIR-97</ce:italic> 
                           <ce:cross-ref refid="bib56" id="crosref0345">[56]</ce:cross-ref>) and completed by iterative cycles of full-matrix least squares refinement on <ce:italic>F</ce:italic>
                           <ce:inf loc="post">o</ce:inf>
                           <ce:sup loc="post">2</ce:sup> and <ce:italic>ΔF</ce:italic> synthesis using the <ce:italic>SHELXL-97</ce:italic> 
                           <ce:cross-ref refid="bib57" id="crosref0350">[57]</ce:cross-ref> program (<ce:italic>WinGX</ce:italic> suite) <ce:cross-ref refid="bib37" id="crosref0355">[37]</ce:cross-ref>. All non-H-atoms were refined anisotropically. The H-atoms positions were introduced in calculated positions in their described geometries and allowed to ride on the attached carbon atom with fixed isotropic thermal parameters. Geometrical calculations were carried out with the program PARST <ce:cross-ref refid="bib58" id="crosref0360">[58]</ce:cross-ref>. The crystal data are given below. CCDC-1478539 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge <ce:italic>via</ce:italic> 
                           <ce:inter-ref xlink:href="http://www.ccdc.cam.ac.uk/conts/retrieving.html" id="intref0010" xlink:type="simple">www.ccdc.cam.ac.uk/conts/retrieving.html</ce:inter-ref> (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: ++44 1223 336 033; or <ce:inter-ref xlink:href="mailto:deposit@ccdc.cam.ac.uk" id="intref0015" xlink:type="simple">deposit@ccdc.cam.ac.uk</ce:inter-ref>).</ce:para>
                        <ce:section id="sec4.3.2.1" view="all">
                           <ce:label>4.3.2.1</ce:label>
                           <ce:section-title id="sectitle0135">Crystal data</ce:section-title>
                           <ce:para id="p0255" view="all">C<ce:inf loc="post">4</ce:inf> H<ce:inf loc="post">7</ce:inf> O<ce:inf loc="post">1</ce:inf> Pt<ce:inf loc="post">1</ce:inf> Cl<ce:inf loc="post">2</ce:inf> N<ce:inf loc="post">3</ce:inf>, <ce:italic>M</ce:italic>
                              <ce:inf loc="post">r</ce:inf> = 379.01 g/mol, Trigonal, Space group <ce:italic>R-3</ce:italic> a = 39.836(2) Å, <ce:italic>c</ce:italic> = 6.724(3) Å, <ce:italic>V</ce:italic> = 9240.8(5) Å<ce:sup loc="post">3</ce:sup>, <ce:italic>Z</ce:italic> = 12, <ce:italic>D</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>calc</ce:italic>
                              </ce:inf> = 2.439 Mg/m<ce:sup loc="post">3</ce:sup>, F(000) = 6120, <ce:italic>R</ce:italic> = 0.026 (reflections collected/unique = 3614/3228), w<ce:italic>R2</ce:italic> = 0.031, <ce:italic>T</ce:italic> = 293(2)K, <ce:italic>GOF</ce:italic> = 1.057. The reflections were collected in the range 1.02° ≤ θ ≤ 25.03° (limiting indices = −47 ≤ h = 47, −47 ≤ k = 47, −8≤l = 7) employing a 0.01 × 0.02 × 0.01 mm<ce:sup loc="post">3</ce:sup> crystal. The residual positive and negative electron densities in the final map were 0.950 and −0.540 eÅ<ce:sup loc="post">−3</ce:sup>.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.3.3" view="all">
                        <ce:label>4.3.3</ce:label>
                        <ce:section-title id="sectitle0140">Stability test</ce:section-title>
                        <ce:para id="p0260" view="all">The stability study of complexes (<ce:bold>Pt-1</ce:bold>, <ce:bold>Pt-2</ce:bold> and <ce:bold>Pt-3</ce:bold>) was performed under physiological conditions through UV-vis spectroscopy at their respective <ce:italic>λ</ce:italic>
                           <ce:inf loc="post">max</ce:inf>. Stock solutions were diluted to a final concentration of 100 μM with 1% DMF. The UV-vis peak profile of the sample was monitored for 48 h at 4 h intervals.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.4" view="all">
                        <ce:label>4.3.4</ce:label>
                        <ce:section-title id="sectitle0145">Log <ce:italic>P</ce:italic>
                           <ce:inf loc="post">ow</ce:inf> determination</ce:section-title>
                        <ce:para id="p0265" view="all">RP-HPLC analysis were performed to correlate the hydrophobicity of the compounds and the Pt(II) complexes with their retention time. The chromatograms were registered using Partisil C18-ODS reversed-phase HPLC column at 25 °C and water/acetonitrile (60:40) as mobile phase with KI as internal standard (flow rate: 1 mL/min; λ = 230 nm). For platinum complexes the same column was used and water (15 mM HCOOH)/MeOH (70:30) mobile phase with KI as internal standard (flow rate of 1 mL/min, λ = 210 nm) <ce:cross-refs refid="bib41 bib42 bib43 bib59" id="crosrefs0090">[41–43,59]</ce:cross-refs>. The calibration curve was realized in comparison with reference compounds chosen in OECD guideline <ce:cross-ref refid="bib54" id="crosref0365">[54]</ce:cross-ref>.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0150">Biology</ce:section-title>
                     <ce:section id="sec4.4.1" view="all">
                        <ce:label>4.4.1</ce:label>
                        <ce:section-title id="sectitle0155">Cell culture</ce:section-title>
                        <ce:para id="p0270" view="all">The following human cancer cell lines have been utilized in the study: HCT-116 (colorectal cancer), DLD1 (colorectal cancer), and MCF-7 (breast cancer). All cultured media were supplemented with penicillin (10,000 U/mL), streptomycin (10 mg/mL), non-essential amino acid and 10% Fetal Calf Serum (FCS). Dulbecco's modified eagle's medium (DMEM) with glutamine was utilized for MCF-7, and DLD-1 cell lines and McCoy's for HCT-116. Cells were incubated with newly synthesized compounds dissolved in DMSO. The same volume of solvent were added to control conditions and did not exceed 0.5% v/v.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.2" view="all">
                        <ce:label>4.4.2</ce:label>
                        <ce:section-title id="sectitle0160">MTT-assay</ce:section-title>
                        <ce:para id="p0275" view="all">The MTT assay was performed according to literature data <ce:cross-refs refid="bib29 bib49" id="crosrefs0095">[29, 49]</ce:cross-refs>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.3" view="all">
                        <ce:label>4.4.3</ce:label>
                        <ce:section-title id="sectitle0165">AlphaScreen-based assay</ce:section-title>
                        <ce:para id="p0280" view="all">It is a bead-based nonradioactive assay system for detecting biomolecular interactions in a microtiter plate format. Binding of biological partners brings donor and acceptor beads into close proximity and as a result, a fluorescent signal between 520 and 620 nm is produced. The AlphaScreen-based assays <ce:cross-refs refid="bib23 bib60" id="crosrefs0100">[23,60]</ce:cross-refs> were performed in a final reaction volume of 25 μL of the assay buffer containing 10 mM HEPES–NaOH (pH 7.4), 50 mM NaCl, 1 mM EDTA (pH 8.0), 0.1% NP-40, and 10 ng/μL BSA in a 96-well microtiter plate at 25 °C. Phospho-Tyr (pTyr) peptide probes used in this study were 5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and (FITC)-GpYDKPHVL for STAT1. Firstly, 75 nM of each SH2-containing protein was incubated with the test compound for 15 min. Each protein sample was then incubated for 90 min with 50 nM of its corresponding FITC-pTyr peptide, and mixed with streptavidin coated donor beads and anti-FITC acceptor beads simultaneously before detection at 570 nm using EnVison Xcite (PerkinElmer).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.4" view="all">
                        <ce:label>4.4.4</ce:label>
                        <ce:section-title id="sectitle0170">
                           <ce:italic>In vivo</ce:italic> antitumor activity in Lewis lung carcinoma</ce:section-title>
                        <ce:para id="p0285" view="all">All experiments were performed according to D.L.G.S. 26/2014 which warrants care of experimental animals in Italy. The research project was approved by the Italian Health Department according to the art. 7 of above mentioned D.L. The LLC cell line was purchased from ECACC, United Kingdom. The LLC cell line was maintained in DMEM (Euroclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Euroclone), 10 mM <ce:small-caps>l</ce:small-caps>-glutamine, 100 U mL<ce:sup loc="post">−1</ce:sup> penicillin, and 100 μg mL<ce:sup loc="post">−1</ce:sup> streptomycin in a 5% CO<ce:inf loc="post">2</ce:inf> air incubator at 37 °C. The LLC was implanted intramuscularly (im) as a 2 × 10<ce:sup loc="post">6</ce:sup> cell inoculum into the right hind leg of 8 week old male and female C57BL mice (24 ± 3 g body weight). After 24 h from tumor implantation, mice were randomly divided into five groups (8 animals per group, 10 controls). From day 7 after tumor inoculation (visible tumor) animals were treated daily with a single dose of compound <ce:bold>3·HCl</ce:bold> and of <ce:bold>Pt-3</ce:bold> complex (75 mg kg<ce:sup loc="post">−1</ce:sup> and 30 mg kg<ce:sup loc="post">−1</ce:sup>, respectively, dissolved in a vehicle solution composed of 20% Cremophor EL (v/v), 20% PEG400 (v/v) and 60% saline solution (v/v)) or with a daily ip dose of cisplatin (1.5 mg kg<ce:sup loc="post">−1</ce:sup> in 0.9% NaCl solution). At day 15, animals were sacrificed, the legs were amputated at the proximal end of the femur, and the inhibition of tumor growth was determined according to the difference in weight of the tumor-bearing leg and the healthy leg of the animals expressed as a percentage referred to the control animals. Body weight was measured at day 1 and every two days from day 7, and was taken as a parameter for systemic toxicity. All the values are the means ± SD of not less than three measurements.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.5" view="all">
                        <ce:label>4.4.5</ce:label>
                        <ce:section-title id="sectitle0175">Determination of intracellular and DNA-bound Pt concentrations</ce:section-title>
                        <ce:para id="p0290" view="all">For the determination of total intracellular <ce:sup loc="pre">195</ce:sup>Pt concentrations, cells were homogenates with lysis buffer containing 0.5% NP-40, 150 mM NaCl and 50 mM Tris-HCl at pH 7.5. The cell monolayer was three times with PBS before the incubation with the lysis buffer for 30 min at 4 °C. Cell lysates were treated then cleared by centrifugation at 14,000<ce:italic>g</ce:italic> for 10 min, and the <ce:sup loc="pre">195</ce:sup>Pt concentrations determined by ICP-MS. The data were normalized with the protein concentrations were determined using the BCA protein assay (Thermo scientific, Rockford, IL USA). The <ce:sup loc="pre">195</ce:sup>Pt concentration bound to DNA was estimated from nuclear DNA extracted as previously described <ce:cross-ref refid="bib29" id="crosref0370">[29]</ce:cross-ref>. The data were normalized with DNA concentrations determined by spectrophotometer determination with NanoDrop system.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.6" view="all">
                        <ce:label>4.4.6</ce:label>
                        <ce:section-title id="sectitle0180">Binding study with 9-ethylguanine and GSH</ce:section-title>
                        <ce:para id="p0295" view="all">The binding studies were directly conducted in NMR tube preparing 1 eq. of <ce:bold>Pt-3</ce:bold> in 20% of 0.9% <ce:italic>w/v</ce:italic> NaCl-D<ce:inf loc="post">2</ce:inf>O solution in DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>. 1eq. of 9-ethylguanine or GSH was added to a solution. The samples were evaluated at different times by <ce:sup loc="pre">1</ce:sup>H NMR analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.7" view="all">
                        <ce:label>4.4.7</ce:label>
                        <ce:section-title id="sectitle0185">Western blot analysis</ce:section-title>
                        <ce:para id="p0300" view="all">Cells were washed twice with PBS and lysed by incubation with a solution of 50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Nonidet-P40, containing a protease inhibitor cocktails (Sigma Aldrich, Milan, Italy) for 30 min on ice. Cell lysates were then cleared by centrifugation at 14,000<ce:italic>g</ce:italic> for 10 min <ce:cross-ref refid="bib61" id="crosref0375">[61]</ce:cross-ref>. Protein samples were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose membrane (GE Healthcare Little Chalfont, Buckinghamshire, UK) and subsequently immunoblotted with primary antibody following appropriate secondary fluorescently labeled antibody and acquired with the Odissey FC system (LI-COR). Quantitative densitometric analyses were performed with Image Studio software (LI-COR). The following antibodies were utilized: monoclonal antibody anti p53 and β-tubulin (SIGMA), anti-pSTAT3 (Abcam) and anti-STAT3 (Santa-Cruz Biotechnology).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.8" view="all">
                        <ce:label>4.4.8</ce:label>
                        <ce:section-title id="sectitle0190">Luciferase reporter gene assay</ce:section-title>
                        <ce:para id="p0305" view="all">STAT3 reporter HeLa stable cells (Signosis Inc) were incubated in a 96-well microplate for 24 h. Cells were pretreated with test compounds for 2 h, and 10 ng/ml (w/v) of Oncostatin M were applied and incubated for 4 h. Cells were washed with medium not supplemented with phenol red, and Steady-Glo<ce:sup loc="post">®</ce:sup> reagent (Promega) was applied. After 15 min incubation, the signals were detected by ARVO Light 1420 (PerkinElmer Life Sciences). The relative signal intensity was calculated in each well as the ratio for the mean signal of vehicle. In parallel with the procedure, CellTiter-Glo (CTG) Luminescent Cell Viability Assay (Promega) was performed for checking the viability of the cells.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.9" view="all">
                        <ce:label>4.4.9</ce:label>
                        <ce:section-title id="sectitle0195">AlexaFluor488-maleimide labeled STAT3 competition assay</ce:section-title>
                        <ce:section id="sec4.4.9.1" view="all">
                           <ce:label>4.4.9.1</ce:label>
                           <ce:section-title id="sectitle0200">Pre-treatment</ce:section-title>
                           <ce:para id="p0310" view="all">The recombinant human STAT3 protein (0.3 μM) was incubated with the test compound in 100 mM HEPES for 2 h at 25 °C. Alexa Fluor 488 C5 maleimide (50 μM) was added to the mixture and incubated for further 2 h at 25 °C. Samples were diluted in SDS-PAGE sample buffer without 2-mercaptoethanol and run on an SDS-PAGE gel. Fluorescence of Alexa-labeled STAT3 was analyzed with FUJIFILM LAS-3000 image analyzer (excitation/emission: 493/516 nm.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.4.9.2" view="all">
                           <ce:label>4.4.9.2</ce:label>
                           <ce:section-title id="sectitle0205">Post-treatment</ce:section-title>
                           <ce:para id="p0315" view="all">The recombinant human STAT3 protein (0.3 μM) was incubated with Alexa Fluor 488 C5 maleimide (50 μM) in 100 mM HEPES for 2 h at 25 °C. The test compound was added to the mixture and incubated for further 2 h at 25 °C. Samples were diluted in SDS-PAGE sample buffer without 2-mercaptoethanol and run on an SDS-PAGE gel. Fluorescence of Alexa-labeled STAT3 was analyzed with FUJIFILM LAS-3000 image analyzer (excitation/emission: 493/516 nm)</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.4.10" view="all">
                        <ce:label>4.4.10</ce:label>
                        <ce:section-title id="sectitle0210">Statistical analysis</ce:section-title>
                        <ce:para id="p0320" view="all">All data shown are representative of at least three replicate experiments. Data are expressed as mean ± SD. Statistical analyses were performed using the unpaired Student's <ce:italic>t</ce:italic>-test. P values < 0.05 were considered significant. The concentration of compounds required to reduce by 50% the cell viability (EC<ce:inf loc="post">50</ce:inf>) was calculated by nonlinear regression curve (SigmaPlot software; Systat Software, Inc., Point Richmond, CA).</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0215">Acknowledgments</ce:section-title>
               <ce:para id="p0325" view="all">This study was supported by funds from <ce:grant-sponsor id="gs1" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">PRIN 2010–2011</ce:grant-sponsor> (<ce:grant-number refid="gs1">20105YY2HL_007</ce:grant-number>). Authors also thank <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Fondazione Confalonieri</ce:grant-sponsor> (Fellowship 2015) for the financial support. BM Kwon was supported by the <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Bio-Synergy Research Project</ce:grant-sponsor> (<ce:grant-number refid="gs3">2012M3A9C4048777</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0220">Supplementary data</ce:section-title>
                  <ce:para id="p0330" view="all">The following is the supplementary data related to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Online data</ce:label>
                           <ce:alt-text role="short" id="alttext0015">Online data</ce:alt-text>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523417301745/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0225">Supplementary data</ce:section-title>
                  <ce:para id="p0335" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2017.03.017" id="intref0020" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2017.03.017</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0230">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Alderden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Hambley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery and development of cisplatin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Educ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>83</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>728</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Rosenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Vancamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Trosko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.H.</ce:given-name>
                                 <ce:surname>Mansour</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platinum compounds: a new class of potent antitumour agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>222</sb:volume-nr>
                              </sb:series>
                              <sb:date>1969</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>385</sb:first-page>
                              <sb:last-page>386</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Arnesano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Natile</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Coord. Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>253</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2070</sb:first-page>
                              <sb:last-page>2081</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Raymond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Faivre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Woynarowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Cvitkovic</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cellular and Molecular Pharmacology Of Oxaliplatin1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>227</sb:first-page>
                              <sb:last-page>235</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kelland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The resurgence of platinum-based cancer chemotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>573</sb:first-page>
                              <sb:last-page>584</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Di Pasqua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Goodisman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Dabrowiak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Understanding how the platinum anticancer drug carboplatin works: from the bottle to the cell</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Inorg. Chim. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>389</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29</sb:first-page>
                              <sb:last-page>35</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Rabik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dolan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular mechanisms of resistance and toxicity associated with platinating agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Treat. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9</sb:first-page>
                              <sb:last-page>23</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Fuertes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Alonso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Pérez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>645</sb:first-page>
                              <sb:last-page>662</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Lippard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Direct cellular responses to platinum-induced DNA damage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1387</sb:first-page>
                              <sb:last-page>1407</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Gonzalez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Fuertes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Alonso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Perez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Is cisplatin-induced cell death always produced by apoptosis?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>657</sb:first-page>
                              <sb:last-page>663</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fraser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Dan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Tsang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>p53 is a determinant of x-linked inhibitor of apoptosis protein/akt-mediated chemoresistance in human ovarian cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7081</sb:first-page>
                              <sb:last-page>7088</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1159</sb:first-page>
                              <sb:last-page>1168</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.-M.</ce:given-name>
                                 <ce:surname>Che</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.-M.</ce:given-name>
                                 <ce:surname>Siu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metal complexes in medicine with a focus on enzyme inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>255</sb:first-page>
                              <sb:last-page>261</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat proteins and oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investigation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1139</sb:first-page>
                              <sb:last-page>1142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.X.</ce:given-name>
                                 <ce:surname>Claret</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e54565</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Campbell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Larner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Carter-Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. (New York, N.Y.)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>269</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>81</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Resetca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20669</sb:first-page>
                              <sb:last-page>20679</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophysical Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>322</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1005</sb:first-page>
                              <sb:last-page>1011</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Boström</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hogner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Llinàs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Wellner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Plowright</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oxadiazoles in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1817</sb:first-page>
                              <sb:last-page>1830</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Masciocchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>567</sb:first-page>
                              <sb:last-page>597</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokotagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Furuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Otsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a new series of STAT3 inhibitors by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miyata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Iizuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Komiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kume</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Omiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sugino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mitsuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakasu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamaguchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>411</sb:first-page>
                              <sb:last-page>418</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Jeon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-H.</ce:given-name>
                                 <ce:surname>Son</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-M.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2′-Benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>279</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6911</sb:first-page>
                              <sb:last-page>6920</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.-S.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Masciocchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pedretti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-M.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Legnani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Toma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>MedChemComm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>156</sb:first-page>
                              <sb:last-page>164</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Masciocchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Toma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-C.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Legnani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ureido-pyridazinone derivatives: insights into the structural and conformational properties for STAT3 inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4907</sb:first-page>
                              <sb:last-page>4912</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Masciocchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pedretti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Legnani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Toma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nakano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>MedChemComm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>592</sb:first-page>
                              <sb:last-page>599</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ferri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Facchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegrino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ricci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Curigliano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Rimoldi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2538</sb:first-page>
                              <sb:last-page>2547</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Rimoldi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Facchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lucchini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Castiglioni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Marchianò</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ferri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>
                                 <ce:italic>In vitro</ce:italic> anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1907</sb:first-page>
                              <sb:last-page>1913</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Fenton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Aldrich-Wright</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In vivo studies of a platinum(ii) metallointercalator</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Commun.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5613</sb:first-page>
                              <sb:last-page>5615</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gabriele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Porta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Facchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Galli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Rimoldi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Romeo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ricci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ferri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sparatore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ark. part ii</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>235</sb:first-page>
                              <sb:last-page>250</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Sagar Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.K.</ce:given-name>
                                 <ce:surname>Subramanyam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Iyengar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A new novel and practical one pot methodology for conversion of alcohols to amines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Synth. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2233</sb:first-page>
                              <sb:last-page>2237</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dreos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Siega</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Scagliola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Randaccio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nardin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tavagnacco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bevilacqua</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, characterization, and electrochemical properties of dinuclear complexes assembled from asymmetric CoIII bis(dioximates) and boronic acids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Inorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2005</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3936</sb:first-page>
                              <sb:last-page>3944</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Egan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Koch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Swan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Clarkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Van Schalkwyk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>
                                 <ce:italic>In Vitro</ce:italic> antimalarial activity of a series of cationic 2,2â€˜-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2926</sb:first-page>
                              <sb:last-page>2934</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Berners-Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Sadler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Prog. Nucl. Magn. Reson. Spectrosc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>98</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Farrugia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>WinGX suite for small-molecule single-crystal crystallography</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Appl. Crystallogr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>837</sb:first-page>
                              <sb:last-page>838</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Llorca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Molins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Espinosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Mata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Miravitlles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Caubet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Moreno</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dichloro(d-methionine-N,S)platinum(II) at 130 K</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Crystallogr. Sect. C</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>804</sb:first-page>
                              <sb:last-page>806</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bondi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>van der Waals volumes and radii</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Phys. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:date>1964</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>441</sb:first-page>
                              <sb:last-page>451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.W.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-M.</ce:given-name>
                                 <ce:surname>Che</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hui</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural and spectroscopic studies on Pt·Pt and π−π interactions in luminescent multinuclear cyclometalated platinum(II) Homologues tethered by oligophosphine auxiliaries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>126</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7639</sb:first-page>
                              <sb:last-page>7651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Platts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Hibbs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Hambley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Calculation of the hydrophobicity of platinum drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>472</sb:first-page>
                              <sb:last-page>474</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Oldfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Platts</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5227</sb:first-page>
                              <sb:last-page>5237</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.V.</ce:given-name>
                                 <ce:surname>Tetko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Jaroszewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Platts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kuduk-Jaworska</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Calculation of lipophilicity for Pt(II) complexes: Experimental comparison of several methods</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1424</sb:first-page>
                              <sb:last-page>1437</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reist</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Christiansen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Christoffersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-A.</ce:given-name>
                                 <ce:surname>Carrupt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Low configurational stability of amfepramone and cathinone: mechanism and kinetics of chiral inversion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chirality</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>469</sb:first-page>
                              <sb:last-page>473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mohr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Weiß</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Spreitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Schmid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chiral separation of new cathinone- and amphetamine-related designer drugs by gas chromatography–mass spectrometry using trifluoroacetyl-l-prolyl chloride as chiral derivatization reagent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chromatogr. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1269</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>352</sb:first-page>
                              <sb:last-page>359</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting STAT3 affects melanoma on multiple fronts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Metastasis Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>315</sb:first-page>
                              <sb:last-page>327</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Klostergaard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chapter 7-STAT3 signaling in cancer: small molecule intervention as therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>Anti-angiogenesis Drug Discovery and Development,</sb:maintitle>
                              </sb:title>
                              <sb:date>2014</sb:date>
                              <sb:publisher>
                                 <sb:name>Elsevier</sb:name>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>216</sb:first-page>
                              <sb:last-page>267</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gandin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Trenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Porchia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Tisato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Giorgetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Zanusso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Trevisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Marzano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Homoleptic phosphino copper(i) complexes with <ce:italic>in vitro</ce:italic> and in vivo dual cytotoxic and anti-angiogenic activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Metallomics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1497</sb:first-page>
                              <sb:last-page>1507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ferri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cazzaniga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mazzarella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Curigliano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lucchini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zerla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gandolfi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Facchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pellizzoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Rimoldi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: a comparative study with cisplatin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2379</sb:first-page>
                              <sb:last-page>2386</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Johnstone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Lippard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The chiral potential of phenanthriplatin and its influence on guanine binding</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>136</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2126</sb:first-page>
                              <sb:last-page>2134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lemaire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-H.</ce:given-name>
                                 <ce:surname>Fouchet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kozelka</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of platinum N7-binding to deoxyguanosine and deoxyadenosine on the H8 and H2 chemical shifts. A quantitative analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>271</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Min</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-Q.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Combating the drug resistance of cisplatin using a platinum prodrug based delivery system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6742</sb:first-page>
                              <sb:last-page>6747</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.J.</ce:given-name>
                                 <ce:surname>Jansen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brouwer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Reedijk</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>89</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>197</sb:first-page>
                              <sb:last-page>202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <ce:other-ref id="sref54">
                        <ce:textref>OECD Guideline for Testing of Chemicals-Partition Coefficient (n-octanol/water), High Performance Liquid Chromatography (HPLC) Method, in.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Krause</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Herbst-Irmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Sheldrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stalke</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Appl. Crystallogr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Altomare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Burla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Camalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Cascarano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Giacovazzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Guagliardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.G.</ce:given-name>
                                 <ce:surname>Moliterni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Polidori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Spagna</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SIR97: a new tool for crystal structure determination and refinement</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Appl. Crystallogr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115</sb:first-page>
                              <sb:last-page>119</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Sheldrick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SHELX97, Programs for Crystal Structure Analysis (Release 97-2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>1998</sb:date>
                              <sb:publisher>
                                 <sb:name>University of Göttingen</sb:name>
                                 <sb:location>Germany</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nardelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PARST95-an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Appl. Crystallogr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>659</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Platts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Oldfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Reif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Palmucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gabano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Osella</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The RP-HPLC measurement and QSPR analysis of log Po/w values of several Pt(II) complexes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1199</sb:first-page>
                              <sb:last-page>1207</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mochizuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Haino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel high-throughput screening system for identifying STAT3–SH2 antagonists</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophysical Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>380</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>627</sb:first-page>
                              <sb:last-page>631</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Greco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Camera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Facchinetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Brambilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegrino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Gelmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tremoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Corsini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ferri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cardiovasc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>366</sb:first-page>
                              <sb:last-page>374</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>